ClinicalTrials.gg
CompletedNCT05415215ProHerUpdated Feb 10, 2026Results posted

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

A Phase 3 interventional study of Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC) and Pertuzumab IV in Early Breast Cancer, Locally Advanced Breast Cancer and Inflammatory Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 45 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Primary conditionInflammatory Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Inflammatory Breast Neoplasms
Why
  1. The study's listed conditions name Inflammatory Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) administration in the home setting compared with the hospital setting during the cross-over period of adjuvant treatment in participants with early or locally advanced/inflammatory human epidermal growth factor receptor 2-positive (HER2+) breast cancer.

02

Conditions studied

  • Early Breast Cancer
  • Locally Advanced Breast Cancer
  • Inflammatory Breast Cancer

Browse trials for

Keywords

  • patient preference
  • home administration
  • fixed-dose combination of pertuzumab and trastuzumab
  • subcutaneous administration
03

In context

Inflammatory Breast Neoplasms Reclassified

112 studies on the registry are indexed under Inflammatory Breast Neoplasms; 7 are open to participants now.

This study's enrollment of 346 is above the median of 58 across 96 interventional studies indexed under Inflammatory Breast Neoplasms.

Browse Inflammatory Breast Neoplasms studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Compared within Inflammatory Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status 0-1
  • Intact skin at planned site of subcutaneous (SC) injections
  • (LVEF) greater than or equal to (≥)55% by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)
  • Negative (HIV) test at screening
  • Negative surface antigen (HBsAg) test at screening
  • Positive hepatitis B surface antibody (HBsAb) test at screening, or negative HBsAb at screening accompanied by either of the following: Negative total hepatitis B core antibody (HBcAb); Positive total HBcAb test followed by a negative (per local laboratory definition) hepatitis B virus (HBV) DNA test
  • Negative virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening
  • For female participants of : agreement to remain abstinent or use and agree to refrain from donating eggs during the treatment period and for 7 months after the final dose of the study treatment
  • For male participants: agreement to remain abstinent or use a condom, and agree to refrain from donating sperm during the treatment period and for 7 months after the final dose of study treatment

Disease-specific Inclusion Criteria:

  • Female and male participants with stage II-IIIC early or locally advanced/inflammatory human epidermal growth factor receptor 2-positive (+) breast cancer
  • Primary tumor >2 centimetres (cm) in diameter, or node-positive disease
  • HER2+ breast cancer confirmed by a local laboratory prior to study enrollment. HER2+ status will be determined based on pretreatment breast material and defined as 3+ by Immunohistochemistry (IHC) and/or positive by HER2 amplification by in situ hybridization (ISH) following American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines 2018 and updates (Wolff et al. Arch Pathol Lab Med 2018)
  • Hormone receptor status of the primary tumor determined by local assessment following American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines and updates (Allison et al. J Clin Oncol 2020)
  • Agreement to undergo mastectomy or breast conserving surgery after therapy, including the axillary nodes
  • Availability of formalin-fixed, paraffin-embedded (FFPE) tumor tissue block for local confirmation of HER2 and hormone receptor status following current ASCO/CAP guidelines

Inclusion Criteria for Treatment with Adjuvant PH FDC SC:

  • Completed the neoadjuvant phase of this study and underwent surgery, and achieved pathologic complete response (pCR), defined as eradication of invasive disease in the breast and axilla according to the current American Joint Committee on Cancer (AJCC) staging system classification, and using the resected specimen by the local pathologist on the basis of guidelines to be provided in a pathology manual
  • Adequate wound healing after breast cancer surgery per investigator's assessment to allow initiation of study treatment within less than or equal to (≤)9 weeks of last systemic neoadjuvant therapy

Exclusion criteria

Exclusion Criteria:

  • Stage IV () breast cancer
  • History of concurrent or previously treated non-breast , except for appropriately treated 1) non-melanoma skin cancer and/or 2) in situ carcinomas, including cervix, colon, and skin. A participant with previous invasive non-breast cancer is eligible provided he/she has been disease free for more than 5 years
  • Participants who are pregnant or breastfeeding or intending to become pregnant during the study or within 7 months after the final dose of study treatments
  • Treatment with therapy within 28 days prior to initiation of study treatment
  • Active, unresolved infections at screening requiring treatment
  • Participants who may have had a recent episode of thromboembolism and are still trying to optimize the anticoagulation dose and/or have not normalized their (INR)
  • Serious cardiac illness or medical conditions
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias
  • Inadequate bone marrow function
  • Impaired liver function
  • Renal function with \<50 mL/min using the Cockroft-Gault formula and serum creatinine >1.5x (ULN)
  • Major surgical procedure unrelated to breast cancer within 28 days prior to study entry or anticipation of the need for major surgery during the course of study treatment
  • Current severe, uncontrolled systemic disease that may interfere with planned treatment
  • Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the study
  • Treatment with a (e.g., FluMist) in the 30 days prior to initiation of study treatment, or anticipation of need for such a vaccine during treatment or within 90 days after the final dose of study treatment
  • Known active liver disease, for example, active viral hepatitis infection, hepatic disorders, or sclerosing cholangitis
  • Known to any of the study drugs, , and/or murine proteins or a history of severe allergic or immunological reactions, e.g., difficult to control asthma
  • Current chronic daily treatment with
  • Assessment by the investigator as being unable or unwilling to comply with the requirements of the protocol

Cancer-specific Exclusion Criteria for Phase:

  • Participants who have received any previous systemic therapy for treatment or prevention of breast cancer, or previous chest irradiation for the treatment of cancer
  • Participants who have a past history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) if they have received any systemic therapy for its treatment or radiation therapy to the ipsi- or contralateral breast cancer
  • Participants with high-risk for breast cancer who have received chemopreventive drugs in the past
  • Participants with multicentric breast cancer, unless all tumors are +
  • Participants with bilateral breast cancer
  • Participants who have undergone an excisional of primary tumor and/or axillary lymph nodes
  • Axillary lymph node dissection (ALND) prior to initiation of neoadjuvant therapy
  • Sentinel lymph node biopsy (SLNB) prior to neoadjuvant therapy

Exclusion Criterion for Treatment with Adjuvant Trastuzumab Emtansine (Arm E):

  • Current Grade ≥3 peripheral neuropathy (according to the v5.0)
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
346 participants (actual)

Study arms

  • Other
    Arm A: Pertuzumab IV and Trastuzumab IV Plus Investigator's Choice of Chemotherapy

    During the neoadjuvant phase, the enrolled participants randomized to this arm will receive treatment with pertuzumab and trastuzumab intravenously (PH IV) plus investigator's choice of chemotherapy (Option 1, 2, or 3). With chemotherapy Option 1, PH IV will be administered at each cycle from Cycles 1 to 6 (1 cycle is 3 weeks); with chemotherapy Options 2 and 3, PH IV will be administered once per cycle from Cycles 5 to 8 (1 cycle is 3 weeks).

    Drug: Pertuzumab IV · Drug: Trastuzumab IV · Drug: Investigator's Choice of Chemotherapy · Procedure: Surgery · Radiation: Radiotherapy

  • Other
    Arm B: PH FDC SC Plus Investigator's Choice of Chemotherapy

    During the neoadjuvant phase, the enrolled participants randomized to this arm will receive treatment with the fixed dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) plus investigator's choice of chemotherapy (Option 1, 2, or 3). With chemotherapy Option 1, PH FDC SC will be administered at each cycle from Cycles 1 to 6 (1 cycle is 3 weeks); with chemotherapy Options 2 and 3, PH FDC SC will be administered once per cycle from Cycles 5 to 8 (1 cycle is 3 weeks).

    Drug: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC) · Drug: Investigator's Choice of Chemotherapy · Procedure: Surgery · Radiation: Radiotherapy

  • Experimental
    Arm C: Adjuvant PH FDC SC in Hospital, Then at Home

    During the adjuvant phase, participants who have achieved pCR after surgery will be treated with 2 cycles of PH FDC SC in the hospital (run-in period). After completion of the last cycle of radiotherapy and the last cycle of PH FDC SC (run-in period), participants will then be randomized with a ratio of 1:1 into one of two treatment arms (Arm C or D) in a cross-over treatment period to receive the next 6 cycles of PH FDC SC treatment. Participants in Arm C will receive 3 cycles of PH FDC SC in the hospital and then 3 cycles of PH FDC SC in the home setting. After the cross-over treatment period, participants will receive the remaining PH FDC SC treatment cycles required to complete the planned 18 cycles of HER2-directed therapy, unless of disease recurrence, unacceptable toxicity, or withdrawal. Study treatment during this treatment continuation period will be administered either in the hospital or in the home setting as selected by the participant at the end of the crossover period.

    Drug: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)

  • Experimental
    Arm D: Adjuvant PH FDC SC at Home, Then in Hospital

    During the adjuvant phase, participants who have achieved pCR after surgery will be treated with 2 cycles of PH FDC SC in the hospital (run-in period). After completion of the last cycle of radiotherapy and the last cycle of PH FDC SC (run-in period), participants will then be randomized with a ratio of 1:1 into one of two treatment arms (Arm C or D) in a cross-over treatment period to receive the next 6 cycles of PH FDC SC treatment. Participants in Arm D will receive 3 cycles of PH FDC SC in the home setting and then 3 cycles of PH FDC SC in the hospital. After the cross-over treatment period, participants will receive the remaining PH FDC SC treatment cycles required to complete the planned 18 cycles of HER2-directed therapy, unless of disease recurrence, unacceptable toxicity, or withdrawal. Study treatment during this treatment continuation period will be administered either in the hospital or in the home setting as selected by the participant at the end of the crossover period.

    Drug: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)

  • Other
    Arm E: Adjuvant Trastuzumab Emtansine

    Participants with pathological evidence of residual invasive carcinoma in the breast or axillary lymph nodes following completion of preoperative therapy and surgery will enter Arm E to receive trastuzumab emtansine for 14 cycles. Trastuzumab emtansine will be administered IV in the hospital as per prescribing information.

    Drug: Trastuzumab Emtansine

Interventions

  • DrugFixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)

    Drug page: Pertuzumab/Trastuzumab/Hyaluronidase-zzxf

    PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).

    Also known as: PHESGO®, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab, Trastuzumab, and rHuPH20, RO7198574, RG6264

  • Pertuzumab is given as a fixed dose of 840 mg intravenous (IV) loading dose and then 420 mg IV for subsequent maintenance doses once every 3 weeks.

    Also known as: Perjeta®, RO4368451

  • Trastuzumab is given as an 8 milligram per kilogram (mg/kg) intravenous (IV) loading dose and then 6 mg/kg IV for subsequent maintenance doses once every 3 weeks.

    Also known as: Herceptin®, RO0452317

  • Trastuzumab emtansine will be given at a dose of 3.6 mg/kg by intravenous (IV) infusion, once every 3 weeks.

    Also known as: Kadcyla®, ado-trastuzumab emtansine, T-DM1, RO5304020

  • DrugInvestigator's Choice of Chemotherapy

    Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles); Option 3: Dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles).

  • ProcedureSurgery

    After completing their neoadjuvant therapy, participants will undergo surgical resection for early or locally advanced HER2+ breast cancer (if eligible for surgery). Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice. The surgery cannot be performed ≤2 weeks from the last systemic neoadjuvant therapy and must be performed ≤6 weeks after the last systemic neoadjuvant therapy.

  • RadiationRadiotherapy

    After surgery, radiotherapy is to be given as clinically indicated and as per local practice or institutional standards. The selected radiotherapy regimen should be initiated within 4 weeks after surgery.

06

What researchers measure

Primary outcomes

  1. Cross-over Period: Percentage of Participants Who Preferred the Administration of PH FDC SC in the Home Setting Compared With the Hospital Setting in Question 1 of the Patient Preference Questionnaire (PPQ)

    The PPQ was used to evaluate the participant preference for PH FDC SC compared to P+H IV. Participants completed the PPQ, where Question (Q) 1 was: "All things considered, which setting for your treatment did you prefer?" Participants were required to select one of the following options: home, hospital or no preference. The reported results show the percentage of participants who preferred receiving PH FDC SC at home setting over the hospital setting. Percentages were rounded off.

    Time frame: Upon completion of adjuvant cross-over period (Day 1 of Cycle 8 or 9; Cycle length = 21 days)

Secondary outcomes

  1. Neoadjuvant Phase: Percentage of HCPs by Their Responses to Question 1a of HCPQ - Drug Preparation Area

    HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation of P+H IV and/or administration of PH FDC SC completed the following question of the HCPQ: Q1a: "Please indicate which treatment preparation the estimates relate to". HCPs were required to select one of the following options: PH FDC SC or P+H IV. The response to Q1a was used to further assess Q1b: How long did it take to prepare the treatment for use? Percentages were rounded off.

    Time frame: Day 1 of Cycles 1-8 (Cycle length = 21 days)

  2. Neoadjuvant Phase: Duration of Treatment Preparation, According to Healthcare Professionals' Responses to Question 1b of HCPQ - Drug Preparation Area

    HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation of P+H IV and/or administration of PH FDC SC completed the following question of the HCPQ: Q1b: "How long did it take to prepare the treatment for use?" This was a follow up question to Q1a: "Please indicate which treatment preparation the estimates relate to" for which HCPs were required to select one of the following options: PH FDC SC or P+H IV.

    Time frame: Day 1 of Cycles 1-8 (Cycle length = 21 days)

  3. Neoadjuvant Phase: Percentage of HCPs by Their Response to Question 2 of the HCPQ - Drug Preparation Area

    HCP=any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation of P+H IV and/or administration of PH FDC SC completed the following question 2 of the HCPQs: In your opinion, if all P+H IV infusions were switched to PH FDC SC injections, please indicate how strongly you agree/disagree with each of the following statements. 2a: Staff will have increased availability for other tasks in the pharmacy. 2b: Administrative procedures related to PH FDC SC require less time. 2c: Using PH FDC SC provides more flexibility for pharmacy staff in managing their workload. 2d: As PH FDC SC is fixed-dose, potential dosing errors are avoided. 2e: As PH FDC SC is fixed-dose, there is less drug wastage. 2f: Less storage space for PH FDC SC-related supplies is required in the pharmacy, as there is no need for reconstitution. 2g: Number of preparation steps \& staff time commitment are reduced. Percentages were rounded off.

    Time frame: Up to Day 1 of Cycle 8 (Cycle length = 21 days)

  4. Neoadjuvant Phase: Percentage of HCPs by Their Responses to Questions 1a-1e of the HCPQ - Administering Treatment

    HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with administration of P+H IV and/or PH FDC SC completed the following Questions of the HCPQ: Q1a: Please indicate which treatment preparation the estimates relate to. Q1b: Did the participant have existing IV access? Q1c: If new IV access was needed for this cycle of treatment, please indicate what type of IV access was provided. Q1d: What type of existing IV access did the participant have? Q1e: When did the existing IV access place? Percentages were rounded off. PICC = peripherally inserted central catheter.

    Time frame: Day 1 of Cycles 1-8 (Cycle length = 21 days)

  5. Neoadjuvant Phase: Duration of Treatment Administration According to HCPs' Responses to Questions 1c (Sub-part), 1f, and 1g of the HCPQ - Administering Treatment

    HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with administration of P+H IV and/or PH FDC SC completed the following Questions of the HCPQ: Q1c: If new IV access was needed for this cycle of treatment, how long (in minutes) this took to set up? Q1f: How long (in minutes) did it take to administer the treatment (P+H IV or PH FDC SC)? Q1g: How long (in minutes) was the participant in the Treatment Area in total? Percentages have been rounded off.

    Time frame: Day 1 of Cycles 1-8 (Cycle length = 21 days)

  6. Neoadjuvant Phase: Percentage of HCPs by Their Response to Question 2 (2a to 2e) of the HCPQ - Administering Treatment

    HCP was defined as any personnel involved in the drug preparation \&/or drug administration processes. HCPs who have had experience with administration of P+H IV \&/or PH FDC SC completed Q2 (2a-2e) of the HCPQ: In your opinion, if all P+H IV infusions were switched to PH FDC SC injections, please indicate how strongly you agree/disagree with each of the following statements. 2a: Participants may be moved out of the Treatment Area (for infusion treatment) to receive PH FDC SC injections. 2b: PH FDC SC's SC route of administration allows for more flexible treatment scheduling. 2c: Frees up infusion chairs for participants whose treatments can only be given IV. 2d: Waiting list for any P+H IV treatment at the Treatment Area is reduced. 2e: Staff's work burden is reduced, enhancing work performance. The 6 available options were: Strongly Disagree, Disagree, Neutral, Agree, Strongly Agree and Not applicable. Percentages were rounded off.

    Time frame: Up to Cycle 8 (Cycle length = 21 days)

  7. Neoadjuvant Phase: Percentage of HCPs by Their Responses to Question 2 (2f to 2j) of the HCPQ - Administering Treatment

    HCP was defined as any personnel involved in the drug preparation \&/or drug administration processes. HCPs who have had experience with administration of P+H IV \&/or PH FDC SC completed Question 2 (2f to 2j) of the HCPQ: In your opinion, if all P+H IV infusions were switched to PH FDC SC injections, please indicate how strongly you agree/disagree with each of the following statements. 2f: More interaction time between HCPs and participants. 2g: Staff have more time for further professional education/development. 2h: Staff has more time for administrative tasks. 2i: Participants on PH FDC SC spend less time in the Treatment Area. 2j: Participants prefer PH FDC SC to P+H IV. The 6 available options were: Strongly Disagree, Disagree, Neutral, Agree, Strongly Agree and Not applicable. Percentages were rounded off.

    Time frame: Up to Cycle 8 (Cycle length = 21 days)

  8. Neoadjuvant Phase: Percentage of HCPs by Their Responses to Question 3 to 11 of the HCPQ - Administering Treatment

    HCPs who have had experience with administration of P+H IV \&/or PH FDC SC completed Questions 3 to 11 of the HCPQ: Q3: Which was more convenient for the participant? Q4: Which was better for optimising participant care at your institution? Q5: Which required less time to administer (excluding observation period)? Q6: Which required less use of institutional resources (e.g., staff time, facility costs, equipment use)? Q7: Which required less time to administer all the treatment (including IV chemotherapy)? Q8: Which allowed for attending to more participants because of time savings from the mode of administration of pertuzumab and trastuzumab? Q9: During the NP you had to administer IV chemotherapy through participant's IV access. You prefer to accompany IV chemotherapy with? Q10: Which was preferred by participants? Q11: How frequently would you recommend PH FDC SC administration to your participants in the future? Percentages were rounded off.

    Time frame: Up to Cycle 8 (Cycle length = 21 days)

  9. Percentage of Participants Who Achieved pCR Post-surgery

    pCR was defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (i.e., ypT0/Tis ypN0), according to the current American Joint Committee on Cancer (AJCC) staging system classification. Percentages were rounded off.

    Time frame: Up to approximately 7.8 months

  10. Neoadjuvant Phase: Change From Baseline in Health-related Quality of Life (HRQoL) Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ C30) Scores

    EORTC QLQ-C30=cancer-specific instrument consisting of 30 questions that evaluated 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), global health status/quality of life (GHS/QoL) \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning \& symptom items used a 4-point scale, scores ranging from 1=Not at all to 4=Very much. GHS/QoL questions used a 7-point scale, scores ranging from 1=Very poor to 7=Excellent. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for functional/GHS scale=high/healthy level of functioning/better HRQoL \& high score for symptom scale=high level of symptom severity. A positive change from baseline=improvement \& negative change=worsening in QoL \& functioning scales. A positive change from baseline=deterioration \& negative change=improvement in symptom scales.

    Time frame: Baseline, Day 1 of Cycles 6 and 8 (Cycle length = 21 days)

  11. Adjuvant Phase: Change From Baseline in HRQoL Assessed by EORTC QLQ C30 Scores

    EORTC QLQ-C30=cancer-specific instrument consisting of 30 questions that evaluated 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning \& symptom items used a 4-point scale, scores ranging from 1=Not at all to 4=Very much. GHS/QoL questions used a 7-point scale, scores ranging from 1=Very poor to 7=Excellent. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for functional/GHS scale=high/healthy level of functioning/better HRQoL \& high score for symptom scale=high level of symptom severity. A positive change from baseline=improvement \& negative change=worsening in QoL \& functioning scales. A positive change from baseline=deterioration \& negative change=improvement in symptom scales.

    Time frame: Baseline (Cycle 1) of Run-in Period; Day 1 of Cycles 1, 3, and 6 in the Cross-over Period (Cycle length = 21 days)

  12. Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 1a and 1c of the HCPQ - Drug Preparation Area

    HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1a: Where was the treatment prepared? Q1c: Which healthcare professionals were involved in the treatment preparation processes? The 4 available response options for Q1a were: Participant's home, Hospital pharmacy, Day oncology unit, or Other. The 5 available response options for Q1c were: Physician, Nurse, Pharmacist, All of them or Other. Percentages were rounded off.

    Time frame: Day 1 of Cycles 3 and 6 (Cycle length = 21 days)

  13. Adjuvant Cross-over Period: Duration of Treatment Preparation, According to HCPs' Responses to Question 1b of the HCPQ - Drug Preparation Area

    HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation and/or administration of PH FDC SC completed the following parts of question Q1b: Q1b(1): How long did it take to prepare the treatment for use? Q1b(2): Time from the preparation place to reach the participant's home.

    Time frame: Day 1 of Cycles 3 and 6 (Cycle length = 21 days)

  14. Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 2, 3 and 4 of the HCPQ - Drug Preparation Area

    HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation and/or administration of PH FDC SC completed the questions 2, 3 and 4 of the HCPQ: Q2: If all PH FDC SC injections were switched from an in-hospital setting to the participant´s home, please indicate how strongly you agree or disagree with each of the following statements: 2a: Staff will have increased availability for other tasks in the hospital´s pharmacy. 2b: Administrative procedures related to PH FDC SC will require less time. 2c: Number of preparation steps and staff time commitment are reduced. The 5 response options were: Strongly disagree, Disagree, Neutral, Agree, Strongly agree or Not applicable. Q3: Which took less time? Q4: Which required less use of institutional resources? The 4 available options were: Participant's home, In hospital, No difference, or Unsure. Percentages were rounded off.

    Time frame: Day 1 of Cycle 6 (Cycle length = 21 days)

  15. Adjuvant Cross-over Period: Duration of Administering Treatment, According to HCPs' Responses to Question 1a to 1f of the HCPQ - Administering Treatment

    HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1a: How long did it take to travel to the participant's home to administer PH FDC SC? Q1b: How long did it take for the participant to travel to the hospital to receive PH FDC SC? Q1c: How long did it take to administer PH FDC SC? Q1d: How long was the participant treatment time? Q1e: How much time did the participant spend in hospital? Q1f: How much time did you spend at the participant's home? From arrival to departure time.

    Time frame: Day 1 of Cycles 3 and 6 (Cycle length = 21 days)

  16. Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 1g, 1h, and 1i of the HCPQ - Administering Treatment

    HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1g. Does the participant still have implanted IV access? The 2 available responses were: Yes or No. Q1h: If question 1g was answered 'No', when was the IV access removed? The 3 available responses were: After surgery and before initiating adjuvant treatment; After initiating adjuvant treatment, or Not applicable. Q1i: If question 1g was answered 'Yes', what is the main reason to keep the IV access? The 5 available responses were: Local protocol; Risk of recurrence; Participant preference; Not applicable, or Other. Percentages were rounded off.

    Time frame: Day 1 of Cycles 3 and 6 (Cycle length = 21 days)

  17. Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 1j, 1k, and 1l of the HCPQ - Administering Treatment

    HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1j: How long do you keep implanted IV access in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer participants with pCR following surgery in your institution? The 5 available responses were: \<12 months, ≥12 months, 18 months, \<24 months, ≥24 months. Q1k: When is the decision point for you to decide to remove IV access for early HER2+ breast cancer participants? The 6 available responses were: Before surgery, After surgery, After PCR results, After completion of full adjuvant therapy, After completion of IV antineoplastic within adjuvant therapy, and Other. Q1l: Do you consider it necessary to keep implanted IV access knowing that the participant's treatment will be SC until the full 18 cycles? The 3 available responses were: Yes, No, and Unsure. Percentages were rounded off.

    Time frame: Day 1 of Cycle 6 (Cycle length = 21 days)

  18. Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Question 2 of the HCPQ - Administering Treatment

    HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following question of the HCPQ: Q2: If all PH FDC SC injections were switched from an in-hospital setting to the participant's home, please indicate how strongly you agree/disagree with each of the following statements: 2a: PH FDC SC's SC route of administration allows for more flexible treatment scheduling. 2b: Frees up infusion chairs or outpatient procedure rooms used to administer SC injections. 2c: Waiting list for infusion chairs or outpatient procedure rooms is reduced. 2d: Staff's work burden is reduced, enhancing work performance. 2e: More interaction time between HCPs and participants on IV treatment. 2f: Staff has more time for administrative tasks. 2g: Participants will spend less time in hospital. 2h: Participants prefer PH FDC SC at home. The 6 available responses were: Strongly disagree, Disagree, Neutral, Agree, Strongly agree, \& Not applicable.

    Time frame: Day 1 of Cycle 6 (Cycle length = 21 days)

  19. Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 3 to 7 of the HCPQ - Administering Treatment

    HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q3: Which was more convenient for the participant? Q4: Which was better for optimising participant care? Q5: Which required less use of institutional resources? Q6: Which was preferred by participants? The 4 responses available were: Participant's home, In hospital, No difference, and Unsure. Q7: How frequently would you recommend PH FDC SC at home to your participants in the future? The 3 responses available were: Always, Sometimes, and Never. Percentages were rounded off.

    Time frame: Day 1 of Cycle 6 (Cycle length = 21 days)

  20. Adjuvant Phase: HRQoL Assessed by EORTC QLQ C30 Scores in Participants Treated With Trastuzumab Emtansine IV

    EORTC QLQ-C30=cancer-specific instrument consisting of 30 questions that evaluated 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning \& symptom items used a 4-point scale, scores ranging from 1=Not at all to 4=Very much. GHS/QoL questions used a 7-point scale, scores ranging from 1=Very poor to 7=Excellent. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for functional/GHS scale=high/healthy level of functioning/better HRQoL \& high score for symptom scale=high level of symptom severity. A positive change from baseline=improvement \& negative change=worsening in QoL \& functioning scales. A positive change from baseline=deterioration \& negative change=improvement in symptom scales.

    Time frame: Day 1 of Cycles 1 and 6 (1 Cycle = 21 days)

  21. Percentage of Participants Who Selected the Administration of PH FDC SC in the Home Setting Compared With the Hospital Setting in the Treatment Continuation Period

    The percentage of participants who chose to receive PH FDC SC in the home setting or in the hospital setting during the treatment continuation period is reported.

    Time frame: Upon completion of adjuvant cross-over period (Day 1 of Cycle 8 or 9; Cycle length = 21 days)

  22. Neoadjuvant Phase: Number of Participants With Adverse Events (AEs), Grade ≥ 3 AEs, Serious AEs (SAEs), and Cardiac AEs

    AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with use of a study treatment, whether or not considered related to the study treatment. SAE=any untoward medical occurrence that, at any dose: Results in death; Is life threatening; Requires inpatient hospitalization/prolongation of existing hospitalization; Results in persistent disability/incapacity \&/or is a congenital anomaly/birth defect. Cardiac AEs=asymptomatic decline in left ventricular ejection fraction (LVEF) of ≥10% from baseline to an LVEF \<50%; asymptomatic decline in LVEF requiring treatment/leading to discontinuation of study treatment; congestive heart failure (CHF). AEs ≥Grade 3=marked limitation of physical activity. Comfortable at rest, but any ordinary activity causes fatigue, palpitation/dyspnea; Inability to carry any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. Any physical activity leads to discomfort.

    Time frame: From initiation of study treatment until 28 days after the last treatment cycle (up to approximately 7.4 months)

  23. Neoadjuvant Phase: Number of Participants With Premature Withdrawal From PH FDC SC and P+H IV Due to AEs

    An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study intervention. Participants who discontinued the study due to AEs are reported here.

    Time frame: Up to Cycle 8 (1 Cycle = 21 days)

  24. Adjuvant Cross-over Period: Number of Participants With AEs, Grade ≥ 3 AEs, SAEs, and Cardiac AEs

    AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with use of a study treatment, whether or not considered related to the study treatment. SAE=any untoward medical occurrence that, at any dose: Results in death; Is life threatening; Requires inpatient hospitalization/prolongation of existing hospitalization; Results in persistent disability/incapacity \&/or is a congenital anomaly/birth defect. Cardiac AEs=asymptomatic decline in LVEF of ≥10% from baseline to an LVEF \<50%; asymptomatic decline in LVEF requiring treatment/leading to discontinuation of study treatment; CHF. AEs ≥Grade 3=marked limitation of physical activity. Comfortable at rest, but any ordinary activity causes fatigue, palpitation/dyspnea; Inability to carry any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. Any physical activity leads to discomfort.

    Time frame: From initiation of study treatment until 28 days after the last treatment cycle (up to approximately 5.8 months)

  25. Adjuvant Cross-over Period: Number of Participants With Premature Withdrawal From PH FDC SC Due to AEs

    An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study intervention. Participants who discontinued the study due to AEs are reported here.

    Time frame: Up to Cycle 6 (Cycle length = 21 days)

  26. Treatment Continuation Period and Trastuzumab Emtansine IV Period: Number of Participants With AEs, Grade ≥ 3 AEs, SAEs, and Cardiac AEs

    AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with use of a study treatment, whether or not considered related to the study treatment. SAE=any untoward medical occurrence that, at any dose: Results in death; Is life threatening; Requires inpatient hospitalization/prolongation of existing hospitalization; Results in persistent disability/incapacity \&/or is a congenital anomaly/birth defect. Cardiac AEs=asymptomatic decline in LVEF of ≥10% from baseline to an LVEF \<50%; asymptomatic decline in LVEF requiring treatment/leading to discontinuation of study treatment; CHF. AEs ≥Grade 3=marked limitation of physical activity. Comfortable at rest, but any ordinary activity causes fatigue, palpitation/dyspnea; Inability to carry any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. Any physical activity leads to discomfort.

    Time frame: From initiation of study treatment until 28 days after the last treatment cycle (up to approximately 3.5 years)

  27. Treatment Continuation Period and Trastuzumab Emtansine IV Period: Number of Participants With Premature Withdrawal From PH FDC SC and Trastuzumab Emtansine IV Due to AEs

    An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study intervention. Participants who discontinue study due to AEs will be reported.

    Time frame: From initiation of study treatment in the adjuvant phase until 28 days after the last treatment cycle (up to approximately 3.5 years)

07

Results

Posted Jan 12, 2026

Participant flow

A total of 347 participants (1 participant was re-randomized to the same PH FDC SC arm) with early or locally advanced or inflammatory human epidermal growth factor receptor 2-positive (HER2+) breast cancer took part in the study at 45 investigative sites across 17 countries. The study is still ongoing. The health care professionals (HCPs) treating the participants were not enrolled in the study. The HCPs only completed the HCP questionnaire (HCPQ).

Neoadjuvant Phase
Participant flow — Neoadjuvant Phase
MilestoneArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SCAdjuvant Run-in Phase: PH FDC SC in HospitalArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in HospitalArm C, Adjuvant Continuation Phase: PH FDC SCArm D, Adjuvant Continuation Phase: PH FDC SCArm E, Adjuvant Phase: Trastuzumab Emtansine IV
Started116231000000
Neoadjuvant safety analysis set (sasab)115228000000
Completed neoadjuvant treatment114210000000
Completed surgery113207000000
Continued into the run-in period68126000000
Continued into trastuzumab emtansine iv arm4374000000
Switched from iv to sc treatment10000000
Completed111200000000
Not completed531000000
Withdrew: Adverse event08000000
Withdrew: Death04000000
Withdrew: Withdrawal by subject211000000
Withdrew: Progressive disease02000000
Withdrew: Reason not specified14000000
Withdrew: Treatment intolerance11000000
Withdrew: Lost to follow-up11000000
Adjuvant Phase: Run-in Period
Participant flow — Adjuvant Phase: Run-in Period
MilestoneArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SCAdjuvant Run-in Phase: PH FDC SC in HospitalArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in HospitalArm C, Adjuvant Continuation Phase: PH FDC SCArm D, Adjuvant Continuation Phase: PH FDC SCArm E, Adjuvant Phase: Trastuzumab Emtansine IV
Started0019400000
Completed0019400000
Not completed00000000
Adjuvant Phase: Cross-over Period
Participant flow — Adjuvant Phase: Cross-over Period
MilestoneArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SCAdjuvant Run-in Phase: PH FDC SC in HospitalArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in HospitalArm C, Adjuvant Continuation Phase: PH FDC SCArm D, Adjuvant Continuation Phase: PH FDC SCArm E, Adjuvant Phase: Trastuzumab Emtansine IV
Started0009896000
Received ≥1 dose of adjuvant cross-over treatment0009796000
Completed0009693000
Not completed00023000
Withdrew: Adverse event00011000
Withdrew: Withdrawal by subject00011000
Withdrew: Treatment intolerance00001000
Adjuvant Phase: Continuation Period
Participant flow — Adjuvant Phase: Continuation Period
MilestoneArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SCAdjuvant Run-in Phase: PH FDC SC in HospitalArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in HospitalArm C, Adjuvant Continuation Phase: PH FDC SCArm D, Adjuvant Continuation Phase: PH FDC SCArm E, Adjuvant Phase: Trastuzumab Emtansine IV
Started0000096930
Chose home setting for continuation treatment0000066500
Chose hospital setting for continuation treatment0000030420
Received ≥1 dose of continuation treatment0000096890
Completed0000082810
Not completed0000014120
Withdrew: Adverse event00000010
Withdrew: Non-compliance with study drug00000100
Withdrew: Withdrawal by subject00000100
Withdrew: Progressive disease00000110
Withdrew: Reason not specified00000010
Withdrew: Ongoing in treatment000001190
Adjuvant Phase: Trastuzumab Emtansine IV
Participant flow — Adjuvant Phase: Trastuzumab Emtansine IV
MilestoneArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SCAdjuvant Run-in Phase: PH FDC SC in HospitalArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in HospitalArm C, Adjuvant Continuation Phase: PH FDC SCArm D, Adjuvant Continuation Phase: PH FDC SCArm E, Adjuvant Phase: Trastuzumab Emtansine IV
Started0000000117
Completed000000077
Not completed000000040
Withdrew: Adverse event00000005
Withdrew: Death00000001
Withdrew: Withdrawal by subject00000002
Withdrew: Physician decision00000001
Withdrew: Reason not specified00000002
Withdrew: Treatment intolerance00000004
Withdrew: Ongoing in treatment000000025
Follow-up Period
Participant flow — Follow-up Period
MilestoneArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SCAdjuvant Run-in Phase: PH FDC SC in HospitalArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in HospitalArm C, Adjuvant Continuation Phase: PH FDC SCArm D, Adjuvant Continuation Phase: PH FDC SCArm E, Adjuvant Phase: Trastuzumab Emtansine IV
Started00000858787
Completed00000404034
Not completed00000454753
Withdrew: Ongoing in follow-up00000444551
Withdrew: Adverse event00000010
Withdrew: Lost to follow-up00000110
Withdrew: Withdrawal by subject00000002

Outcome measures

PrimaryCross-over Period: Percentage of Participants Who Preferred the Administration of PH FDC SC in the Home Setting Compared With the Hospital Setting in Question 1 of the Patient Preference Questionnaire (PPQ)

The PPQ was used to evaluate the participant preference for PH FDC SC compared to P+H IV. Participants completed the PPQ, where Question (Q) 1 was: "All things considered, which setting for your treatment did you prefer?" Participants were required to select one of the following options: home, hospital or no preference. The reported results show the percentage of participants who preferred receiving PH FDC SC at home setting over the hospital setting. Percentages were rounded off.

Time frame:
Upon completion of adjuvant cross-over period (Day 1 of Cycle 8 or 9; Cycle length = 21 days)
Reported as:
Number · percentage of participants
Cross-over Period: Percentage of Participants Who Preferred the Administration of PH FDC SC in the Home Setting Compared With the Hospital Setting in Question 1 of the Patient Preference Questionnaire (PPQ)
percentage of participantsArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital
Home69.059.0
Hospital23.039.8
No Preference8.01.2
SecondaryNeoadjuvant Phase: Percentage of HCPs by Their Responses to Question 1a of HCPQ - Drug Preparation Area

HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation of P+H IV and/or administration of PH FDC SC completed the following question of the HCPQ: Q1a: "Please indicate which treatment preparation the estimates relate to". HCPs were required to select one of the following options: PH FDC SC or P+H IV. The response to Q1a was used to further assess Q1b: How long did it take to prepare the treatment for use? Percentages were rounded off.

Time frame:
Day 1 of Cycles 1-8 (Cycle length = 21 days)
Reported as:
Number · percentage of HCPs
Neoadjuvant Phase: Percentage of HCPs by Their Responses to Question 1a of HCPQ - Drug Preparation Area
percentage of HCPsArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SC
Cycle 1 Day 1: PH FDC SC0100
Cycle 1 Day 1: P+H IV1000
Cycle 2 Day 1: PH FDC SC0100
Cycle 2 Day 1: P+H IV1000
Cycle 3 Day 1: PH FDC SC0100
Cycle 3 Day 1: P+H IV1000
Cycle 4 Day 1: PH FDC SC1.6100
Cycle 4 Day 1: P+H IV98.40
Cycle 5 Day 1: PH FDC SC0.9100
Cycle 5 Day 1: P+H IV99.10
Cycle 6 Day 1: PH FDC SC0.9100
Cycle 6 Day 1: P+H IV99.10
Cycle 7 Day 1: PH FDC SC0100
Cycle 7 Day 1: P+H IV1000
Cycle 8 Day 1: PH FDC SC0100
Cycle 8 Day 1: P+H IV1000
SecondaryNeoadjuvant Phase: Duration of Treatment Preparation, According to Healthcare Professionals' Responses to Question 1b of HCPQ - Drug Preparation Area

HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation of P+H IV and/or administration of PH FDC SC completed the following question of the HCPQ: Q1b: "How long did it take to prepare the treatment for use?" This was a follow up question to Q1a: "Please indicate which treatment preparation the estimates relate to" for which HCPs were required to select one of the following options: PH FDC SC or P+H IV.

Time frame:
Day 1 of Cycles 1-8 (Cycle length = 21 days)
Reported as:
Median · minutes
Neoadjuvant Phase: Duration of Treatment Preparation, According to Healthcare Professionals' Responses to Question 1b of HCPQ - Drug Preparation Area
minutesArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SC
Cycle 1 Day 120.0 (1 to 120)5.0 (0 to 30)
Cycle 2 Day 120.5 (1 to 50)5.0 (0 to 40)
Cycle 3 Day 120.0 (1 to 50)5.0 (1 to 35)
Cycle 4 Day 120.0 (1 to 50)5.0 (1 to 30)
Cycle 5 Day 120.0 (1 to 110)5.0 (1 to 52)
Cycle 6 Day 120.0 (1 to 410)5.0 (1 to 131)
Cycle 7 Day 113.5 (4 to 90)4.0 (1 to 45)
Cycle 8 Day 115.0 (4 to 90)5.0 (1 to 45)
SecondaryNeoadjuvant Phase: Percentage of HCPs by Their Response to Question 2 of the HCPQ - Drug Preparation Area

HCP=any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation of P+H IV and/or administration of PH FDC SC completed the following question 2 of the HCPQs: In your opinion, if all P+H IV infusions were switched to PH FDC SC injections, please indicate how strongly you agree/disagree with each of the following statements. 2a: Staff will have increased availability for other tasks in the pharmacy. 2b: Administrative procedures related to PH FDC SC require less time. 2c: Using PH FDC SC provides more flexibility for pharmacy staff in managing their workload. 2d: As PH FDC SC is fixed-dose, potential dosing errors are avoided. 2e: As PH FDC SC is fixed-dose, there is less drug wastage. 2f: Less storage space for PH FDC SC-related supplies is required in the pharmacy, as there is no need for reconstitution. 2g: Number of preparation steps \& staff time commitment are reduced. Percentages were rounded off.

Time frame:
Up to Day 1 of Cycle 8 (Cycle length = 21 days)
Reported as:
Number · percentage of HCPs
Neoadjuvant Phase: Percentage of HCPs by Their Response to Question 2 of the HCPQ - Drug Preparation Area
percentage of HCPsArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SC
Q2a: Strongly Disagree1.12.4
Q2a: Disagree3.42.4
Q2a: Neutral13.511.0
Q2a: Agree25.838.4
Q2a: Strongly Agree52.839.6
Q2a: Not Applicable3.46.1
Q2b: Strongly Disagree4.52.4
Q2b: Disagree12.415.2
Q2b: Neutral13.514.6
Q2b: Agree18.025.6
Q2b: Strongly Agree47.235.4
Q2b: Not Applicable4.56.7
Q2c: Strongly Disagree1.11.2
Q2c: Disagree4.52.4
Q2c: Neutral11.214.0
Q2c: Agree28.141.5
Q2c: Strongly Agree50.634.1
Q2c: Not Applicable4.56.7
Q2d: Strongly Disagree1.11.2
Q2d: Disagree2.22.4
Q2d: Neutral2.27.9
Q2d: Agree28.136.0
Q2d: Strongly Agree61.846.3
Q2d: Not Applicable4.56.1
Q2e: Strongly Disagree1.11.2
Q2e: Disagree3.43.7
Q2e: Neutral1.16.1
Q2e: Strongly Agree31.535.4
Q2e: Agree58.447.6
Q2e: Not Available4.56.1
Q2f: Strongly Disagree1.11.2
Q2f: Disagree5.66.1
Q2f: Neutral10.112.2
Q2f: Strongly Agree24.733.5
Q2f: Agree53.940.9
Q2f: Not available4.56.1
Q2g: Strongly Disagree1.11.8
Q2g: Disagree7.94.2
Q2g: Neutral7.96.1
Q2g: Strongly Agree23.636.4
Q2g: Agree56.244.8
Q2g: Not available3.46.7
SecondaryNeoadjuvant Phase: Percentage of HCPs by Their Responses to Questions 1a-1e of the HCPQ - Administering Treatment

HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with administration of P+H IV and/or PH FDC SC completed the following Questions of the HCPQ: Q1a: Please indicate which treatment preparation the estimates relate to. Q1b: Did the participant have existing IV access? Q1c: If new IV access was needed for this cycle of treatment, please indicate what type of IV access was provided. Q1d: What type of existing IV access did the participant have? Q1e: When did the existing IV access place? Percentages were rounded off. PICC = peripherally inserted central catheter.

Time frame:
Day 1 of Cycles 1-8 (Cycle length = 21 days)
Reported as:
Number · percentage of HCPs
Neoadjuvant Phase: Percentage of HCPs by Their Responses to Questions 1a-1e of the HCPQ - Administering Treatment
percentage of HCPsArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SC
Cycle 1 Day 1: Q1a: PH FDC SC0100
Cycle 1 Day 1: Q1a: P+H IV1000
Cycle 1 Day 1: Q1b: Yes24.20
Cycle 1 Day 1: Q1b: No75.8100
Cycle 1 Day 1: Q1c: Peripheral Vein Cannulation90.7100
Cycle 1 Day 1: Q1c: PICC00
Cycle 1 Day 1: Q1c: Central Venous Catheter9.30
Cycle 1 Day 1: Q1d: Central Venous Catheter40.00
Cycle 1 Day 1: Q1d: PICC33.350.0
Cycle 1 Day 1: Q1d: Port-a-Cath26.750.0
Cycle 1 Day 1: Q1d: Tunneled Central Venous Catheter00
Cycle 1 Day 1: Q1e: Within 7 Days Prior Today50.016.7
Cycle 1 Day 1: Q1e: > 7 < 14 Days Prior Today033.3
Cycle 1 Day 1: Q1e: > 14 < 30 Days Prior Today00
Cycle 1 Day 1: Q1e: Other50.050.0
Cycle 2 Day 1: Q1a: PH FDC SC0100
Cycle 2 Day 1: Q1a: P+H IV1000
Cycle 2 Day 1: Q1b: Yes23.060.0
Cycle 2 Day 1: Q1b: No77.040.0
Cycle 2 Day 1: Q1c: Peripheral Vein Cannulation88.666.7
Cycle 2 Day 1: Q1c: PICC00
Cycle 2 Day 1: Q1c: Central Venous Catheter11.433.3
Cycle 2 Day 1: Q1d: Central Venous Catheter35.740.0
Cycle 2 Day 1: Q1d: PICC28.620.0
Cycle 2 Day 1: Q1d: Port-a-Cath35.740.0
Cycle 2 Day 1: Q1d: Tunneled Central Venous Catheter00
Cycle 2 Day 1: Q1e: Within 7 Days Prior Today00
Cycle 2 Day 1: Q1e: > 7 < 14 Days Prior Today00
Cycle 2 Day 1: Q1e: > 14 < 30 Days Prior Today16.762.5
Cycle 2 Day 1: Q1e: Other83.337.5
Cycle 3 Day 1: Q1a: PH FDC SC0100
Cycle 3 Day 1: Q1a: P+H IV1000
Cycle 3 Day 1: Q1b: Yes26.2100
Cycle 3 Day 1: Q1b: No73.80
Cycle 3 Day 1: Q1c: Peripheral Vein Cannulation88.1100
Cycle 3 Day 1: Q1c: PICC2.40
Cycle 3 Day 1: Q1c: Central Venous Catheter9.50
Cycle 3 Day 1: Q1d: Central Venous Catheter33.357.1
Cycle 3 Day 1: Q1d: PICC33.328.6
Cycle 3 Day 1: Q1d: Port-a-Cath33.314.3
Cycle 3 Day 1: Q1d: Tunneled Central Venous Catheter00
Cycle 3 Day 1: Q1e: Within 7 Days Prior Today16.716.7
Cycle 3 Day 1: Q1e: > 7 < 14 Days Prior Today08.3
Cycle 3 Day 1: Q1e: > 14 < 30 Days Prior Today025.0
Cycle 3 Day 1: Q1e: Other83.350.0
Cycle 4 Day 1: Q1a: PH FDC SC1.6100
Cycle 4 Day 1: Q1a: P+H IV98.40
Cycle 4 Day 1: Q1b: Yes32.250.0
Cycle 4 Day 1: Q1b: No67.850.0
Cycle 4 Day 1: Q1c: Peripheral Vein Cannulation89.750.0
Cycle 4 Day 1: Q1c: PICC00
Cycle 4 Day 1: Q1c: Central Venous Catheter10.350.0
Cycle 4 Day 1: Q1d: Central Venous Catheter30.050.0
Cycle 4 Day 1: Q1d: PICC35.00
Cycle 4 Day 1: Q1d: Port-a-Cath35.050.0
Cycle 4 Day 1: Q1d: Tunneled Central Venous Catheter00
Cycle 4 Day 1: Q1e: Within 7 Days Prior Today07.7
Cycle 4 Day 1: Q1e: > 7 < 14 Days Prior Today00
Cycle 4 Day 1: Q1e: > 14 < 30 Days Prior Today14.338.5
Cycle 4 Day 1: Q1e: Other85.753.8
Cycle 5 Day 1: Q1a: PH FDC SC0.9100
Cycle 5 Day 1: Q1a: P+H IV99.10
Cycle 5 Day 1: Q1b: Yes33.325.0
Cycle 5 Day 1: Q1b: No66.775.0
Cycle 5 Day 1: Q1c: Port-a-cath1.40
Cycle 5 Day 1: Q1c: Peripheral Vein Cannulation93.283.3
Cycle 5 Day 1: Q1c: PICC00
Cycle 5 Day 1: Q1c: Central Venous Catheter5.516.7
Cycle 5 Day 1: Q1d: Central Venous Catheter19.416.7
Cycle 5 Day 1: Q1d: PICC41.70
Cycle 5 Day 1: Q1d: Port-a-Cath33.383.3
Cycle 5 Day 1: Q1d: Tunneled Central Venous Catheter5.60
Cycle 5 Day 1: Q1e: Within 7 Days Prior Today21.17.4
Cycle 5 Day 1: Q1e: > 7 < 14 Days Prior Today10.511.1
Cycle 5 Day 1: Q1e: > 14 < 30 Days Prior Today15.829.6
Cycle 5 Day 1: Q1e: Other52.651.9
Cycle 6 Day 1: Q1a: PH FDC SC0.9100
Cycle 6 Day 1: Q1a: P+H IV99.10
Cycle 6 Day 1: Q1b: Yes34.940.0
Cycle 6 Day 1: Q1b: No65.160.0
Cycle 6 Day 1: Q1c: Port-a-cath2.80
Cycle 6 Day 1: Q1c: Peripheral Vein Cannulation94.4100
Cycle 6 Day 1: Q1c: PICC00
Cycle 6 Day 1: Q1c: Central Venous Catheter2.80
Cycle 6 Day 1: Q1d: Central Venous Catheter16.20
Cycle 6 Day 1: Q1d: PICC43.214.3
Cycle 6 Day 1: Q1d: Port-a-Cath32.485.7
Cycle 6 Day 1: Q1d: Tunneled Central Venous Catheter8.10
Cycle 6 Day 1: Q1e: Within 7 Days Prior Today25.06.5
Cycle 6 Day 1: Q1e: > 7 < 14 Days Prior Today09.7
Cycle 6 Day 1: Q1e: > 14 < 30 Days Prior Today15.029.0
Cycle 6 Day 1: Q1e: Other60.054.8
Cycle 7 Day 1: Q1a: PH FDC SC0100
Cycle 7 Day 1: Q1a: P+H IV1000
Cycle 7 Day 1: Q1b: Yes28.166.7
Cycle 7 Day 1: Q1b: No71.933.3
Cycle 7 Day 1: Q1c: Peripheral Vein Cannulation97.650.0
Cycle 7 Day 1: Q1c: PICC00
Cycle 7 Day 1: Q1c: Central Venous Catheter2.450.0
Cycle 7 Day 1: Q1d: Central Venous Catheter6.30
Cycle 7 Day 1: Q1d: PICC50.020.0
Cycle 7 Day 1: Q1d: Port-a-Cath25.080.0
Cycle 7 Day 1: Q1d: Tunneled Central Venous Catheter18.80
Cycle 7 Day 1: Q1e: Within 7 Days Prior Today38.511.8
Cycle 7 Day 1: Q1e: > 7 < 14 Days Prior Today017.6
Cycle 7 Day 1: Q1e: > 14 < 30 Days Prior Today15.45.9
Cycle 7 Day 1: Q1e: Other46.264.7
Cycle 8 Day 1: Q1a: PH FDC SC0100
Cycle 8 Day 1: Q1a: P+H IV1000
Cycle 8 Day 1: Q1b: Yes33.30
Cycle 8 Day 1: Q1b: No66.7100
Cycle 8 Day 1: Q1c: Peripheral Vein Cannulation97.4100
Cycle 8 Day 1: Q1c: PICC00
Cycle 8 Day 1: Q1c: Central Venous Catheter2.60
Cycle 8 Day 1: Q1d: Central Venous Catheter10.50
Cycle 8 Day 1: Q1d: PICC47.4100
Cycle 8 Day 1: Q1d: Port-a-Cath31.60
Cycle 8 Day 1: Q1d: Tunneled Central Venous Catheter10.50
Cycle 8 Day 1: Q1e: Within 7 Days Prior Today20.014.3
Cycle 8 Day 1: Q1e: > 7 < 14 Days Prior Today13.328.6
Cycle 8 Day 1: Q1e: > 14 < 30 Days Prior Today20.00
Cycle 8 Day 1: Q1e: Other46.757.1
SecondaryNeoadjuvant Phase: Duration of Treatment Administration According to HCPs' Responses to Questions 1c (Sub-part), 1f, and 1g of the HCPQ - Administering Treatment

HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with administration of P+H IV and/or PH FDC SC completed the following Questions of the HCPQ: Q1c: If new IV access was needed for this cycle of treatment, how long (in minutes) this took to set up? Q1f: How long (in minutes) did it take to administer the treatment (P+H IV or PH FDC SC)? Q1g: How long (in minutes) was the participant in the Treatment Area in total? Percentages have been rounded off.

Time frame:
Day 1 of Cycles 1-8 (Cycle length = 21 days)
Reported as:
Median · minutes
Neoadjuvant Phase: Duration of Treatment Administration According to HCPs' Responses to Questions 1c (Sub-part), 1f, and 1g of the HCPQ - Administering Treatment
minutesArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SC
Cycle 1 Day 1: Q1c5.0 (1 to 150)5.0 (1 to 308)
Cycle 1 Day 1: Q1f180.0 (60 to 390)8.0 (5 to 30)
Cycle 1 Day 1: Q1g420.0 (120 to 520)180.0 (8 to 424)
Cycle 2 Day 1: Q1c5.0 (1 to 18)5.0 (2 to 6)
Cycle 2 Day 1: Q1f82.5 (5 to 360)5.0 (5 to 190)
Cycle 2 Day 1: Q1g300.0 (90 to 503)180.0 (5 to 330)
Cycle 3 Day 1: Q1c5.0 (1 to 20)10.0 (5 to 10)
Cycle 3 Day 1: Q1f90.0 (5 to 360)5.0 (3 to 159)
Cycle 3 Day 1: Q1g280.0 (90 to 500)180.0 (6 to 480)
Cycle 4 Day 1: Q1c5.0 (2 to 20)6.5 (5 to 10)
Cycle 4 Day 1: Q1f90.0 (14 to 365)5.0 (3 to 15)
Cycle 4 Day 1: Q1g270.0 (30 to 560)170.0 (6 to 480)
Cycle 5 Day 1: Q1c5.0 (1 to 150)5.0 (1 to 10)
Cycle 5 Day 1: Q1f145.0 (8 to 360)8.0 (4 to 250)
Cycle 5 Day 1: Q1g294.0 (30 to 552)150.0 (5 to 420)
Cycle 6 Day 1: Q1c5.0 (1 to 25)5.0 (2 to 5)
Cycle 6 Day 1: Q1f90.0 (8 to 360)5.0 (4 to 80)
Cycle 6 Day 1: Q1g260.0 (35 to 510)150.0 (5 to 370)
Cycle 7 Day 1: Q1c5.0 (1 to 30)3.0 (3 to 3)
Cycle 7 Day 1: Q1f90.0 (8 to 210)5.0 (4 to 75)
Cycle 7 Day 1: Q1g190.0 (40 to 480)115.0 (5 to 360)
Cycle 8 Day 1: Q1c5.0 (1 to 20)5.0 (4 to 8)
Cycle 8 Day 1: Q1f90.0 (5 to 180)5.0 (3 to 25)
Cycle 8 Day 1: Q1g180.0 (60 to 535)120.0 (6 to 345)
SecondaryNeoadjuvant Phase: Percentage of HCPs by Their Response to Question 2 (2a to 2e) of the HCPQ - Administering Treatment

HCP was defined as any personnel involved in the drug preparation \&/or drug administration processes. HCPs who have had experience with administration of P+H IV \&/or PH FDC SC completed Q2 (2a-2e) of the HCPQ: In your opinion, if all P+H IV infusions were switched to PH FDC SC injections, please indicate how strongly you agree/disagree with each of the following statements. 2a: Participants may be moved out of the Treatment Area (for infusion treatment) to receive PH FDC SC injections. 2b: PH FDC SC's SC route of administration allows for more flexible treatment scheduling. 2c: Frees up infusion chairs for participants whose treatments can only be given IV. 2d: Waiting list for any P+H IV treatment at the Treatment Area is reduced. 2e: Staff's work burden is reduced, enhancing work performance. The 6 available options were: Strongly Disagree, Disagree, Neutral, Agree, Strongly Agree and Not applicable. Percentages were rounded off.

Time frame:
Up to Cycle 8 (Cycle length = 21 days)
Reported as:
Number · percentage of HCPs
Neoadjuvant Phase: Percentage of HCPs by Their Response to Question 2 (2a to 2e) of the HCPQ - Administering Treatment
percentage of HCPsArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SC
Q2a: Strongly Disagree1.03.0
Q2a: Disagree8.213.4
Q2a: Neutral14.413.4
Q2a: Agree36.128.7
Q2a: Strongly Agree32.033.5
Q2a: Not Applicable8.27.9
Q2b: Strongly Disagree02.4
Q2b: Disagree9.26.0
Q2b: Neutral12.213.9
Q2b: Agree37.834.3
Q2b: Strongly Agree33.735.5
Q2b: Not Applicable7.17.8
Q2c: Strongly Disagree1.03.0
Q2c: Disagree9.26.0
Q2c: Neutral10.210.8
Q2c: Agree32.735.5
Q2c: Strongly Agree39.837.3
Q2c: Not Applicable7.17.2
Q2d: Strongly Disagree01.8
Q2d: Disagree8.26.0
Q2d: Neutral15.315.7
Q2d: Agree34.737.3
Q2d: Strongly Agree35.731.9
Q2d: Not Applicable6.17.2
Q2e: Strongly Disagree03.6
Q2e: Disagree5.13.6
Q2e: Neutral27.625.5
Q2e: Agree26.527.3
Q2e: Strongly Agree34.732.7
Q2e: Not Applicable6.17.3
SecondaryNeoadjuvant Phase: Percentage of HCPs by Their Responses to Question 2 (2f to 2j) of the HCPQ - Administering Treatment

HCP was defined as any personnel involved in the drug preparation \&/or drug administration processes. HCPs who have had experience with administration of P+H IV \&/or PH FDC SC completed Question 2 (2f to 2j) of the HCPQ: In your opinion, if all P+H IV infusions were switched to PH FDC SC injections, please indicate how strongly you agree/disagree with each of the following statements. 2f: More interaction time between HCPs and participants. 2g: Staff have more time for further professional education/development. 2h: Staff has more time for administrative tasks. 2i: Participants on PH FDC SC spend less time in the Treatment Area. 2j: Participants prefer PH FDC SC to P+H IV. The 6 available options were: Strongly Disagree, Disagree, Neutral, Agree, Strongly Agree and Not applicable. Percentages were rounded off.

Time frame:
Up to Cycle 8 (Cycle length = 21 days)
Reported as:
Number · percentage of HCPs
Neoadjuvant Phase: Percentage of HCPs by Their Responses to Question 2 (2f to 2j) of the HCPQ - Administering Treatment
percentage of HCPsArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SC
Q2f: Strongly Disagree02.4
Q2f: Disagree8.24.2
Q2f: Neutral20.434.3
Q2f: Agree33.722.3
Q2f: Strongly Agree31.628.9
Q2f: Not Applicable6.17.8
Q2g: Strongly Disagree2.02.4
Q2g: Disagree5.14.8
Q2g: Neutral25.536.7
Q2g: Agree31.622.9
Q2g: Strongly Agree29.625.3
Q2g: Not Applicable6.17.8
Q2h: Strongly Disagree01.2
Q2h: Disagree6.13.6
Q2h: Neutral23.531.9
Q2h: Agree30.625.9
Q2h: Strongly Agree33.728.9
Q2h: Not Applicable6.18.4
Q2i: Strongly Disagree1.01.8
Q2i: Disagree01.8
Q2i: Neutral4.13.0
Q2i: Agree26.831.9
Q2i: Strongly Agree61.953.0
Q2i: Not Applicable6.28.4
Q2j: Strongly Disagree1.00.6
Q2j: Disagree1.01.8
Q2j: Neutral20.621.7
Q2j: Agree35.131.3
Q2j: Strongly Agree35.132.5
Q2j: Not Applicable7.212.0
SecondaryNeoadjuvant Phase: Percentage of HCPs by Their Responses to Question 3 to 11 of the HCPQ - Administering Treatment

HCPs who have had experience with administration of P+H IV \&/or PH FDC SC completed Questions 3 to 11 of the HCPQ: Q3: Which was more convenient for the participant? Q4: Which was better for optimising participant care at your institution? Q5: Which required less time to administer (excluding observation period)? Q6: Which required less use of institutional resources (e.g., staff time, facility costs, equipment use)? Q7: Which required less time to administer all the treatment (including IV chemotherapy)? Q8: Which allowed for attending to more participants because of time savings from the mode of administration of pertuzumab and trastuzumab? Q9: During the NP you had to administer IV chemotherapy through participant's IV access. You prefer to accompany IV chemotherapy with? Q10: Which was preferred by participants? Q11: How frequently would you recommend PH FDC SC administration to your participants in the future? Percentages were rounded off.

Time frame:
Up to Cycle 8 (Cycle length = 21 days)
Reported as:
Number · percentage of HCPs
Neoadjuvant Phase: Percentage of HCPs by Their Responses to Question 3 to 11 of the HCPQ - Administering Treatment
percentage of HCPsArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SC
Q3: P+H IV8.01.2
Q3: PH FDC SC68.283.9
Q3: No Difference13.68.7
Q3: Unsure10.26.2
Q4: P+H IV5.71.9
Q4: PH FDC SC69.382.1
Q4: No Difference22.713.0
Q4: Unsure2.33.1
Q5: P+H IV00.6
Q5: PH FDC SC92.097.5
Q5: No Difference8.01.9
Q5: Unsure00
Q6: P+H IV00.6
Q6: PH FDC SC83.088.9
Q6: No Difference17.010.5
Q6: Unsure00
Q7: P+H IV1.10
Q7: PH FDC SC96.698.1
Q7: No Difference2.31.9
Q7: Unsure00
Q8: P+H IV00.6
Q8: PH FDC SC73.682.7
Q8: No Difference26.416.7
Q8: Unsure00
Q9: P+H IV12.68.7
Q9: PH FDC SC73.673.9
Q9: No Difference13.817.4
Q9: Unsure00
Q10: P+H IV7.91.2
Q10: PH FDC SC66.373.5
Q10: No Difference10.17.4
Q10: Unsure15.717.9
Q11: Always75.379.1
Q11: Sometimes24.719.0
Q11: Never01.9
SecondaryPercentage of Participants Who Achieved pCR Post-surgery

pCR was defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (i.e., ypT0/Tis ypN0), according to the current American Joint Committee on Cancer (AJCC) staging system classification. Percentages were rounded off.

Time frame:
Up to approximately 7.8 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved pCR Post-surgery
percentage of participantsArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SC
Percentage of Participants Who Achieved pCR Post-surgery60.260.9
SecondaryNeoadjuvant Phase: Change From Baseline in Health-related Quality of Life (HRQoL) Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ C30) Scores

EORTC QLQ-C30=cancer-specific instrument consisting of 30 questions that evaluated 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), global health status/quality of life (GHS/QoL) \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning \& symptom items used a 4-point scale, scores ranging from 1=Not at all to 4=Very much. GHS/QoL questions used a 7-point scale, scores ranging from 1=Very poor to 7=Excellent. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for functional/GHS scale=high/healthy level of functioning/better HRQoL \& high score for symptom scale=high level of symptom severity. A positive change from baseline=improvement \& negative change=worsening in QoL \& functioning scales. A positive change from baseline=deterioration \& negative change=improvement in symptom scales.

Time frame:
Baseline, Day 1 of Cycles 6 and 8 (Cycle length = 21 days)
Reported as:
Mean · score on a scale
Neoadjuvant Phase: Change From Baseline in Health-related Quality of Life (HRQoL) Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ C30) Scores
score on a scaleArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SC
Baseline - GHS/QoL79.86 ± 18.4075.97 ± 20.92
Change at Cycle 6 Day 1 - GHS/QoL-9.43 ± 21.27-7.40 ± 24.64
Change at Cycle 8 Day 1 - GHS/QoL-10.42 ± 19.73-11.75 ± 26.78
Baseline - Physical functioning (PF)91.65 ± 11.8491.84 ± 12.45
Change at Cycle 6 Day 1 - PF-12.65 ± 16.18-16.01 ± 18.56
Change at Cycle 8 Day 1 - PF-16.03 ± 19.28-13.00 ± 16.25
Baseline - Role Functioning (RF)91.88 ± 15.8291.48 ± 19.11
Change at Cycle 6 Day 1 - RF-15.85 ± 28.78-21.18 ± 29.46
Change at Cycle 8 Day 1 - RF-19.87 ± 27.62-14.91 ± 27.98
Baseline - Emotional Functioning (EF)73.41 ± 22.1371.45 ± 22.54
Change at Cycle 6 Day 1 - EF-5.87 ± 26.061.01 ± 25.20
Change at Cycle 8 Day 1 - EF5.29 ± 24.095.85 ± 25.01
Baseline - Cognitive functioning (CF)88.41 ± 19.0188.19 ± 17.62
Change at Cycle 6 Day 1 - CF-12.02 ± 22.39-10.28 ± 23.53
Change at Cycle 8 Day 1 - CF-9.62 ± 25.21-4.74 ± 18.78
Baseline - Social Functioning (SF)86.67 ± 22.9684.30 ± 24.56
Change at Cycle 6 Day 1 - SF-18.03 ± 30.01-15.26 ± 32.55
Change at Cycle 8 Day 1 - SF-14.42 ± 27.82-7.54 ± 25.59
Baseline - Fatigue15.85 ± 20.2916.44 ± 17.74
Change at Cycle 6 Day 1 - Fatigue24.04 ± 26.2327.21 ± 25.91
Change at Cycle 8 Day 1 - Fatigue23.29 ± 24.3320.23 ± 24.31
Baseline - Nausea & Vomiting4.06 ± 11.603.36 ± 10.25
Change at Cycle 6 Day 1 - Nausea & Vomiting19.95 ± 24.6914.80 ± 22.82
Change at Cycle 8 Day 1 - Nausea & Vomiting3.21 ± 20.884.74 ± 17.64
Baseline - Pain12.17 ± 18.2514.13 ± 19.14
Change at Cycle 6 Day 1 - Pain14.21 ± 27.537.79 ± 25.83
Change at Cycle 8 Day 1 - Pain11.86 ± 29.218.07 ± 21.59
Baseline - Dyspnoea4.35 ± 14.326.28 ± 16.45
Change at Cycle 6 Day 1 - Dyspnoea8.74 ± 23.4912.46 ± 24.88
Change at Cycle 8 Day 1 - Dyspnoea13.46 ± 28.976.67 ± 23.11
Baseline - Insomnia25.22 ± 30.1424.51 ± 28.07
Change at Cycle 6 Day 1 - Insomnia4.37 ± 32.483.12 ± 35.33
Change at Cycle 8 Day 1 - Insomnia8.97 ± 40.759.12 ± 33.84
Baseline - Appetite Loss8.41 ± 20.169.72 ± 20.51
Change at Cycle 6 Day 1 - Appetite Loss21.31 ± 32.2223.99 ± 33.89
Change at Cycle 8 Day 1 - Appetite Loss16.03 ± 33.9715.09 ± 35.65
Baseline - Constipation9.57 ± 21.079.87 ± 20.56
Change at Cycle 6 Day 1 - Constipation7.65 ± 29.445.61 ± 25.69
Change at Cycle 8 Day 1 - Constipation2.61 ± 21.953.86 ± 24.73
Baseline - Diarrhoea3.77 ± 13.074.93 ± 14.86
Change at Cycle 6 Day 1 - Diarrhoea25.68 ± 33.5528.04 ± 34.31
Change at Cycle 8 Day 1 - Diarrhoea32.05 ± 26.3727.37 ± 33.68
Baseline - Financial Difficulties26.09 ± 34.1423.17 ± 32.67
Change at Cycle 6 Day 1 - Financial Difficulties6.01 ± 41.957.79 ± 35.93
Change at Cycle 8 Day 1 - Financial Difficulties6.41 ± 28.80-1.40 ± 33.66
SecondaryAdjuvant Phase: Change From Baseline in HRQoL Assessed by EORTC QLQ C30 Scores

EORTC QLQ-C30=cancer-specific instrument consisting of 30 questions that evaluated 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning \& symptom items used a 4-point scale, scores ranging from 1=Not at all to 4=Very much. GHS/QoL questions used a 7-point scale, scores ranging from 1=Very poor to 7=Excellent. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for functional/GHS scale=high/healthy level of functioning/better HRQoL \& high score for symptom scale=high level of symptom severity. A positive change from baseline=improvement \& negative change=worsening in QoL \& functioning scales. A positive change from baseline=deterioration \& negative change=improvement in symptom scales.

Time frame:
Baseline (Cycle 1) of Run-in Period; Day 1 of Cycles 1, 3, and 6 in the Cross-over Period (Cycle length = 21 days)
Reported as:
Mean · score on a scale
Adjuvant Phase: Change From Baseline in HRQoL Assessed by EORTC QLQ C30 Scores
score on a scaleArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital
Baseline - GHS/QoL76.98 ± 17.0971.79 ± 18.63
Change at Cycle 1 Day 1- GHS/QoL0.66 ± 13.720.09 ± 18.57
Change at Cycle 3 Day 1 - GHS/QoL2.08 ± 14.535.15 ± 20.59
Change at Cycle 6 Day 1 - GHS/QoL-0.57 ± 16.612.48 ± 19.99
Baseline - Physical Functioning (PF)82.61 ± 15.8980.35 ± 16.20
Change at Cycle 1 Day 1 - PF2.50 ± 13.191.83 ± 14.44
Change at Cycle 3 Day 1 - PF2.50 ± 13.655.99 ± 14.18
Change at Cycle 6 Day 1 - PF4.13 ± 16.972.46 ± 14.99
Baseline - Role Functioning (RF)78.35 ± 21.4066.67 ± 29.72
Change at Cycle 1 Day 1 - RF4.92 ± 21.6110.62 ± 27.84
Change at Cycle 3 Day 1 - RF6.25 ± 23.6117.23 ± 31.33
Change at Cycle 6 Day 1 - RF9.66 ± 23.5316.07 ± 31.73
Baseline - Emotional Functioning (EF)82.22 ± 19.3176.65 ± 22.61
Change at Cycle 1 Day 1 - EF-1.22 ± 18.440.34 ± 23.55
Change at Cycle 3 Day 1 - EF2.27 ± 16.753.46 ± 18.84
Change at Cycle 6 Day 1 - EF-0.95 ± 21.860.60 ± 19.86
Baseline - Cognitive Functioning (CF)84.54 ± 21.1479.51 ± 24.24
Change at Cycle 1 Day 1 - CF-3.37 ± 21.050.00 ± 22.50
Change at Cycle 3 Day 1 - CF-2.08 ± 21.111.12 ± 21.14
Change at Cycle 6 Day 1 - CF-2.65 ± 22.300.00 ± 24.54
Baseline - Social Functioning (SF)80.58 ± 22.6570.49 ± 25.87
Change at Cycle 1 Day 1 - SF1.69 ± 22.346.59 ± 27.76
Change at Cycle 3 Day 1 - SF1.70 ± 20.699.74 ± 25.23
Change at Cycle 6 Day 1 - SF0.95 ± 21.649.92 ± 25.89
Baseline - Fatigue26.92 ± 21.9231.83 ± 23.56
Change at Cycle 1 Day 1 - Fatigue-3.62 ± 17.55-0.61 ± 24.31
Change at Cycle 3 Day 1 - Fatigue-3.66 ± 18.66-7.99 ± 21.65
Change at Cycle 6 Day 1 - Fatigue-4.42 ± 24.09-4.37 ± 23.84
Baseline - Nausea & Vomiting4.64 ± 10.965.38 ± 11.47
Change at Cycle 1 Day 1 - Nausea & Vomiting-0.95 ± 11.951.83 ± 14.79
Change at Cycle 3 Day 1 - Nausea & Vomiting-0.57 ± 11.43-1.31 ± 10.43
Change at Cycle 6 Day 1 - Nausea & Vomiting-0.95 ± 12.210.99 ± 12.77
Baseline - Pain22.51 ± 20.8428.82 ± 26.10
Change at Cycle 1 Day 1 - Pain-5.30 ± 21.82-7.14 ± 23.46
Change at Cycle 3 Day 1 - Pain-6.37 ± 20.18-9.74 ± 25.97
Change at Cycle 6 Day 1 - Pain-6.06 ± 23.59-8.73 ± 27.19
Baseline - Dyspnoea7.56 ± 17.688.68 ± 17.60
Change at Cycle 1 Day 1 - Dyspnoea1.89 ± 20.440.73 ± 21.65
Change at Cycle 3 Day 1 - Dyspnoea0.00 ± 20.840.75 ± 21.89
Change at Cycle 6 Day 1 - Dyspnoea0.38 ± 17.860.40 ± 21.64
Baseline - Insomnia25.09 ± 27.2328.13 ± 32.92
Change at Cycle 1 Day 1 - Insomnia-1.12 ± 27.274.40 ± 31.51
Change at Cycle 3 Day 1 - Insomnia0.00 ± 27.68-3.00 ± 34.68
Change at Cycle 6 Day 1 - Insomnia0.76 ± 28.580.00 ± 37.67
Baseline - Appetite loss10.65 ± 18.3511.81 ± 21.07
Change at Cycle 1 Day 1 - Appetite loss2.27 ± 27.592.56 ± 29.07
Change at Cycle 3 Day 1 - Appetite loss-0.38 ± 25.010.00 ± 25.62
Change at Cycle 6 Day 1 - Appetite loss-1.14 ± 24.470.00 ± 25.87
Baseline - Constipation13.75 ± 22.9513.89 ± 22.51
Change at Cycle 1 Day 1 - Constipation-2.62 ± 21.450.00 ± 19.25
Change at Cycle 3 Day 1 - Constipation-4.92 ± 23.990.00 ± 25.62
Change at Cycle 6 Day 1 - Constipation-3.79 ± 27.881.98 ± 21.55
Baseline - Diarrhoea12.37 ± 25.1512.15 ± 22.75
Change at Cycle 1 Day 1 - Diarrhoea0.00 ± 26.744.76 ± 33.17
Change at Cycle 3 Day 1 - Diarrhoea-0.38 ± 24.502.25 ± 32.10
Change at Cycle 6 Day 1 - Diarrhoea1.89 ± 29.624.76 ± 32.37
Baseline - Financial difficulties28.18 ± 34.1432.29 ± 34.35
Change at Cycle 1 Day 1 - Financial Difficulties-6.37 ± 24.04-4.40 ± 28.20
Change at Cycle 3 Day 1 - Financial Difficulties-4.92 ± 27.00-6.37 ± 29.68
Change at Cycle 6 Day 1 - Financial Difficulties-2.65 ± 27.32-6.35 ± 30.82
SecondaryAdjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 1a and 1c of the HCPQ - Drug Preparation Area

HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1a: Where was the treatment prepared? Q1c: Which healthcare professionals were involved in the treatment preparation processes? The 4 available response options for Q1a were: Participant's home, Hospital pharmacy, Day oncology unit, or Other. The 5 available response options for Q1c were: Physician, Nurse, Pharmacist, All of them or Other. Percentages were rounded off.

Time frame:
Day 1 of Cycles 3 and 6 (Cycle length = 21 days)
Reported as:
Number · percentage of HCPs
Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 1a and 1c of the HCPQ - Drug Preparation Area
percentage of HCPsArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital
Cycle 3 Day 1: Q1a: Participant's Home090.6
Cycle 3 Day 1: Q1a: Hospital Pharmacy72.69.4
Cycle 3 Day 1: Q1a: Day Oncology Unit17.70
Cycle 3 Day 1: Q1a: Other9.70
Cycle 3 Day 1: Q1c: Physician011.7
Cycle 3 Day 1: Q1c: Nurse35.175.3
Cycle 3 Day 1: Q1c: Pharmacist59.77.8
Cycle 3 Day 1: Q1c: All of Them2.62.6
Cycle 3 Day 1: Q1c: Other2.62.6
Cycle 6 Day 1: Q1a: Participant's Home95.20
Cycle 6 Day 1: Q1a: Hospital Pharmacy4.871.6
Cycle 6: Q1a: Day Oncology Unit020.9
Cycle 6 Day 1: Q1a: Other07.5
Cycle 6 Day 1: Q1c: Physician5.12.8
Cycle 6 Day 1: Q1c: Nurse88.529.2
Cycle 6 Day 1: Q1c: Pharmacist2.658.3
Cycle 6 Day 1: Q1c: All of them2.65.6
Cycle 6 Day 1: Q1c: Other1.34.2
SecondaryAdjuvant Cross-over Period: Duration of Treatment Preparation, According to HCPs' Responses to Question 1b of the HCPQ - Drug Preparation Area

HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation and/or administration of PH FDC SC completed the following parts of question Q1b: Q1b(1): How long did it take to prepare the treatment for use? Q1b(2): Time from the preparation place to reach the participant's home.

Time frame:
Day 1 of Cycles 3 and 6 (Cycle length = 21 days)
Reported as:
Median · minutes
Adjuvant Cross-over Period: Duration of Treatment Preparation, According to HCPs' Responses to Question 1b of the HCPQ - Drug Preparation Area
minutesArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital
Cycle 3 Day 1: Q1b(1)5.0 (1 to 33)5.0 (1 to 30)
Cycle 3 Day 1: Q1b(2)5.0 (0 to 35)1.0 (0 to 70)
Cycle 6 Day 1: Q1b(1)5.0 (1 to 30)4.0 (1 to 15)
Cycle 6 Day 1: Q1b(2)0.0 (0 to 60)3.0 (0 to 30)
SecondaryAdjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 2, 3 and 4 of the HCPQ - Drug Preparation Area

HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with preparation and/or administration of PH FDC SC completed the questions 2, 3 and 4 of the HCPQ: Q2: If all PH FDC SC injections were switched from an in-hospital setting to the participant´s home, please indicate how strongly you agree or disagree with each of the following statements: 2a: Staff will have increased availability for other tasks in the hospital´s pharmacy. 2b: Administrative procedures related to PH FDC SC will require less time. 2c: Number of preparation steps and staff time commitment are reduced. The 5 response options were: Strongly disagree, Disagree, Neutral, Agree, Strongly agree or Not applicable. Q3: Which took less time? Q4: Which required less use of institutional resources? The 4 available options were: Participant's home, In hospital, No difference, or Unsure. Percentages were rounded off.

Time frame:
Day 1 of Cycle 6 (Cycle length = 21 days)
Reported as:
Number · percentage of HCPs
Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 2, 3 and 4 of the HCPQ - Drug Preparation Area
percentage of HCPsArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital
Q2a: Strongly Disagree2.51.3
Q2a: Disagree018.7
Q2a: Neutral6.216.0
Q2a: Agree43.221.3
Q2a: Strongly Agree38.337.3
Q2a: Not Applicable9.95.3
Q2b: Strongly Disagree4.92.7
Q2b: Disagree2.524.3
Q2b: Neutral13.613.5
Q2b: Agree33.318.9
Q2b: Strongly Agree35.835.1
Q2b: Not Applicable9.95.4
Q2c: Strongly Disagree2.50
Q2c: Disagree2.518.9
Q2c: Neutral6.221.6
Q2c: Agree39.516.2
Q2c: Strongly Agree38.337.8
Q2c: Not Applicable11.15.4
Q3: Participant's Home59.522.2
Q3: In hospital2.536.1
Q3: No Difference11.431.9
Q3: Unsure26.69.7
Q4: Participant's Home73.438.9
Q4: In hospital5.136.1
Q4: No Difference8.919.4
Q4: Unsure12.75.6
SecondaryAdjuvant Cross-over Period: Duration of Administering Treatment, According to HCPs' Responses to Question 1a to 1f of the HCPQ - Administering Treatment

HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1a: How long did it take to travel to the participant's home to administer PH FDC SC? Q1b: How long did it take for the participant to travel to the hospital to receive PH FDC SC? Q1c: How long did it take to administer PH FDC SC? Q1d: How long was the participant treatment time? Q1e: How much time did the participant spend in hospital? Q1f: How much time did you spend at the participant's home? From arrival to departure time.

Time frame:
Day 1 of Cycles 3 and 6 (Cycle length = 21 days)
Reported as:
Median · minutes
Adjuvant Cross-over Period: Duration of Administering Treatment, According to HCPs' Responses to Question 1a to 1f of the HCPQ - Administering Treatment
minutesArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital
Cycle 3 Day 1: Q1a82.5 (60 to 105)60.0 (11 to 540)
Cycle 3 Day 1: Q1b60.0 (10 to 420)60.0 (10 to 660)
Cycle 3 Day 1: Q1c5.0 (5 to 13)5.0 (5 to 30)
Cycle 3 Day 1: Q1d30.0 (5 to 540)75.0 (5 to 240)
Cycle 3 Day 1: Q1e120.0 (25 to 586)180.0 (70 to 360)
Cycle 3 Day 1: Q1f—90.0 (40 to 175)
Cycle 6 Day 1: Q1a65.0 (5 to 480)85.0 (50 to 180)
Cycle 6 Day 1: Q1b60.0 (15 to 480)60.0 (5 to 660)
Cycle 6 Day 1: Q1c5.0 (5 to 30)5.0 (5 to 10)
Cycle 6 Day 1: Q1d90.0 (8 to 165)30.0 (5 to 240)
Cycle 6 Day 1: Q1e120.0 (50 to 600)120.0 (25 to 480)
Cycle 6 Day 1: Q1f90.0 (20 to 165)90.0 (90 to 90)
SecondaryAdjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 1g, 1h, and 1i of the HCPQ - Administering Treatment

HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1g. Does the participant still have implanted IV access? The 2 available responses were: Yes or No. Q1h: If question 1g was answered 'No', when was the IV access removed? The 3 available responses were: After surgery and before initiating adjuvant treatment; After initiating adjuvant treatment, or Not applicable. Q1i: If question 1g was answered 'Yes', what is the main reason to keep the IV access? The 5 available responses were: Local protocol; Risk of recurrence; Participant preference; Not applicable, or Other. Percentages were rounded off.

Time frame:
Day 1 of Cycles 3 and 6 (Cycle length = 21 days)
Reported as:
Number · percentage of HCPs
Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 1g, 1h, and 1i of the HCPQ - Administering Treatment
percentage of HCPsArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital
Cycle 3 Day 1: Q1g: Yes35.614.5
Cycle 3 Day 1: Q1g: No64.485.5
Cycle 3 Day 1: Q1h: After Surgery and Before Adjuvant Treatment7.14.3
Cycle 3 Day 1: Q1h: After Initiating Adjuvant Treatment7.110.6
Cycle 3 Day 1: Q1h: Not Applicable85.785.1
Cycle 3 Day 1: Q1i: Local Protocol45.021.4
Cycle 3 Day 1: Q1i: Risk of Recurrence10.014.3
Cycle 3 Day 1: Q1i: Participant Preference25.014.3
Cycle 3 Day 1: Q1i: Not Applicable15.050.0
Cycle 3 Day 1: Q1i: Other5.00
Cycle 6 Day 1: Q1g: Yes23.723.0
Cycle 6 Day 1: Q1g: No76.377.0
Cycle 6 Day 1: Q1h: After Surgery and Before Adjuvant Treatment10.46.4
Cycle 6 Day 1: Q1h: After Initiating Adjuvant Treatment06.4
Cycle 6 Day 1: Q1h: Not Applicable89.687.2
Cycle 6 Day 1: Q1i: Local Protocol27.642.9
Cycle 6 Day 1: Q1i: Risk of Recurrence3.44.8
Cycle 6 Day 1: Q1i: Participant Preference13.84.8
Cycle 6 Day 1: Q1i: Not Applicable51.738.1
Cycle 6 Day 1: Q1i: Other3.49.5
SecondaryAdjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 1j, 1k, and 1l of the HCPQ - Administering Treatment

HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q1j: How long do you keep implanted IV access in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer participants with pCR following surgery in your institution? The 5 available responses were: \<12 months, ≥12 months, 18 months, \<24 months, ≥24 months. Q1k: When is the decision point for you to decide to remove IV access for early HER2+ breast cancer participants? The 6 available responses were: Before surgery, After surgery, After PCR results, After completion of full adjuvant therapy, After completion of IV antineoplastic within adjuvant therapy, and Other. Q1l: Do you consider it necessary to keep implanted IV access knowing that the participant's treatment will be SC until the full 18 cycles? The 3 available responses were: Yes, No, and Unsure. Percentages were rounded off.

Time frame:
Day 1 of Cycle 6 (Cycle length = 21 days)
Reported as:
Number · percentage of HCPs
Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 1j, 1k, and 1l of the HCPQ - Administering Treatment
percentage of HCPsArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital
Q1j: <12 Months10.727.0
Q1j: ≥12 Months28.616.2
Q1j: 18 Months14.316.2
Q1j: <24 Months3.68.1
Q1j: ≥24 Months42.932.4
Q1k: Before Surgery02.6
Q1k: After Surgery2.310.3
Q1k: After PCR Results15.920.5
Q1k: After Completion of Full Adjuvant Therapy15.928.2
Q1k: After Completion of IV Antineoplastic Within Adjuvant Therapy29.55.1
Q1k: Other36.433.3
Q1l: Yes11.937.2
Q1l: No35.737.2
Q1l: Unsure52.425.6
SecondaryAdjuvant Cross-over Period: Percentage of HCPs by Their Responses to Question 2 of the HCPQ - Administering Treatment

HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following question of the HCPQ: Q2: If all PH FDC SC injections were switched from an in-hospital setting to the participant's home, please indicate how strongly you agree/disagree with each of the following statements: 2a: PH FDC SC's SC route of administration allows for more flexible treatment scheduling. 2b: Frees up infusion chairs or outpatient procedure rooms used to administer SC injections. 2c: Waiting list for infusion chairs or outpatient procedure rooms is reduced. 2d: Staff's work burden is reduced, enhancing work performance. 2e: More interaction time between HCPs and participants on IV treatment. 2f: Staff has more time for administrative tasks. 2g: Participants will spend less time in hospital. 2h: Participants prefer PH FDC SC at home. The 6 available responses were: Strongly disagree, Disagree, Neutral, Agree, Strongly agree, \& Not applicable.

Time frame:
Day 1 of Cycle 6 (Cycle length = 21 days)
Reported as:
Number · percentage of HCPs
Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Question 2 of the HCPQ - Administering Treatment
percentage of HCPsArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital
Q2a: Strongly Disagree6.30
Q2a: Disagree01.3
Q2a: Neutral6.38.0
Q2a: Agree30.441.3
Q2a: Strongly Agree55.745.3
Q2a: Not Applicable1.34.0
Q2b: Strongly Disagree6.41.3
Q2b: Disagree05.3
Q2b: Neutral7.76.7
Q2b: Agree29.533.3
Q2b: Strongly Agree55.149.3
Q2b: Not Applicable1.34.0
Q2c: Strongly Disagree7.72.7
Q2c: Disagree01.3
Q2c: Neutral05.3
Q2c: Agree33.333.3
Q2c: Strongly Agree57.753.3
Q2c: Not Applicable1.34.0
Q2d: Strongly Disagree6.50
Q2d: Disagree3.99.3
Q2d: Neutral14.314.7
Q2d: Agree27.325.3
Q2d: Strongly Agree46.842.7
Q2d: Not Applicable1.38.0
Q2e: Strongly Disagree6.40
Q2e: Disagree2.62.7
Q2e: Neutral19.220.0
Q2e: Agree26.933.3
Q2e: Strongly Agree43.633.3
Q2e: Not Applicable1.310.7
Q2f: Strongly Disagree7.70
Q2f: Disagree2.64.0
Q2f: Neutral9.025.3
Q2f: Agree32.122.7
Q2f: Strongly Agree47.440.0
Q2f: Not Applicable1.38.0
Q2g: Strongly Disagree6.40
Q2g: Disagree01.3
Q2g: Neutral06.7
Q2g: Agree24.432.0
Q2g: Strongly Agree67.956.0
Q2g: Not Applicable1.34.0
Q2h: Strongly Disagree6.52.7
Q2h: Disagree3.918.7
Q2h: Neutral15.628.0
Q2h: Agree23.417.3
Q2h: Strongly Agree49.429.3
Q2h: Not Applicable1.34.0
SecondaryAdjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 3 to 7 of the HCPQ - Administering Treatment

HCP was defined as any personnel involved in the drug preparation and/or drug administration processes. HCPs who have had experience with the preparation and/or administration of PH FDC SC completed the following questions of the HCPQ: Q3: Which was more convenient for the participant? Q4: Which was better for optimising participant care? Q5: Which required less use of institutional resources? Q6: Which was preferred by participants? The 4 responses available were: Participant's home, In hospital, No difference, and Unsure. Q7: How frequently would you recommend PH FDC SC at home to your participants in the future? The 3 responses available were: Always, Sometimes, and Never. Percentages were rounded off.

Time frame:
Day 1 of Cycle 6 (Cycle length = 21 days)
Reported as:
Number · percentage of HCPs
Adjuvant Cross-over Period: Percentage of HCPs by Their Responses to Questions 3 to 7 of the HCPQ - Administering Treatment
percentage of HCPsArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital
Q3: Participant's Home84.045.9
Q3: In Hospital7.440.5
Q3: No Difference6.26.8
Q3: Unsure2.56.8
Q4: Participant's Home80.228.4
Q4: In Hospital7.452.7
Q4: No Difference6.212.2
Q4: Unsure6.26.8
Q5: Participant's Home67.940.5
Q5: In Hospital6.227.0
Q5: No Difference17.316.2
Q5: Unsure8.616.2
Q6: Participant's Home79.041.9
Q6: In Hospital11.144.6
Q6: No Difference6.26.8
Q6: Unsure3.76.8
Q7: Always80.243.8
Q7: Sometimes17.343.8
Q7: Never2.512.3
SecondaryAdjuvant Phase: HRQoL Assessed by EORTC QLQ C30 Scores in Participants Treated With Trastuzumab Emtansine IV

EORTC QLQ-C30=cancer-specific instrument consisting of 30 questions that evaluated 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning \& symptom items used a 4-point scale, scores ranging from 1=Not at all to 4=Very much. GHS/QoL questions used a 7-point scale, scores ranging from 1=Very poor to 7=Excellent. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for functional/GHS scale=high/healthy level of functioning/better HRQoL \& high score for symptom scale=high level of symptom severity. A positive change from baseline=improvement \& negative change=worsening in QoL \& functioning scales. A positive change from baseline=deterioration \& negative change=improvement in symptom scales.

Time frame:
Day 1 of Cycles 1 and 6 (1 Cycle = 21 days)

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Selected the Administration of PH FDC SC in the Home Setting Compared With the Hospital Setting in the Treatment Continuation Period

The percentage of participants who chose to receive PH FDC SC in the home setting or in the hospital setting during the treatment continuation period is reported.

Time frame:
Upon completion of adjuvant cross-over period (Day 1 of Cycle 8 or 9; Cycle length = 21 days)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Selected the Administration of PH FDC SC in the Home Setting Compared With the Hospital Setting in the Treatment Continuation Period
Percentage of participantsArm C, Adjuvant Cross-over Phase: PH FDC SC in Hospital, Then at HomeArm D, Adjuvant Cross-Over Phase: PH FDC SC at Home, Then in Hospital
Choice of Home Setting68.854.3
Choice of Hospital Setting31.245.7
SecondaryNeoadjuvant Phase: Number of Participants With Adverse Events (AEs), Grade ≥ 3 AEs, Serious AEs (SAEs), and Cardiac AEs

AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with use of a study treatment, whether or not considered related to the study treatment. SAE=any untoward medical occurrence that, at any dose: Results in death; Is life threatening; Requires inpatient hospitalization/prolongation of existing hospitalization; Results in persistent disability/incapacity \&/or is a congenital anomaly/birth defect. Cardiac AEs=asymptomatic decline in left ventricular ejection fraction (LVEF) of ≥10% from baseline to an LVEF \<50%; asymptomatic decline in LVEF requiring treatment/leading to discontinuation of study treatment; congestive heart failure (CHF). AEs ≥Grade 3=marked limitation of physical activity. Comfortable at rest, but any ordinary activity causes fatigue, palpitation/dyspnea; Inability to carry any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. Any physical activity leads to discomfort.

Time frame:
From initiation of study treatment until 28 days after the last treatment cycle (up to approximately 7.4 months)
Reported as:
Count of participants · Participants
Neoadjuvant Phase: Number of Participants With Adverse Events (AEs), Grade ≥ 3 AEs, Serious AEs (SAEs), and Cardiac AEs
ParticipantsArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SC
AEs113227
SAEs1943
Grade ≥ 3 AEs46103
Cardiac AEs13
SecondaryNeoadjuvant Phase: Number of Participants With Premature Withdrawal From PH FDC SC and P+H IV Due to AEs

An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study intervention. Participants who discontinued the study due to AEs are reported here.

Time frame:
Up to Cycle 8 (1 Cycle = 21 days)
Reported as:
Count of participants · Participants
Neoadjuvant Phase: Number of Participants With Premature Withdrawal From PH FDC SC and P+H IV Due to AEs
ParticipantsArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SC
Neoadjuvant Phase: Number of Participants With Premature Withdrawal From PH FDC SC and P+H IV Due to AEs18
SecondaryAdjuvant Cross-over Period: Number of Participants With AEs, Grade ≥ 3 AEs, SAEs, and Cardiac AEs

AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with use of a study treatment, whether or not considered related to the study treatment. SAE=any untoward medical occurrence that, at any dose: Results in death; Is life threatening; Requires inpatient hospitalization/prolongation of existing hospitalization; Results in persistent disability/incapacity \&/or is a congenital anomaly/birth defect. Cardiac AEs=asymptomatic decline in LVEF of ≥10% from baseline to an LVEF \<50%; asymptomatic decline in LVEF requiring treatment/leading to discontinuation of study treatment; CHF. AEs ≥Grade 3=marked limitation of physical activity. Comfortable at rest, but any ordinary activity causes fatigue, palpitation/dyspnea; Inability to carry any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. Any physical activity leads to discomfort.

Time frame:
From initiation of study treatment until 28 days after the last treatment cycle (up to approximately 5.8 months)
Reported as:
Count of participants · Participants
Adjuvant Cross-over Period: Number of Participants With AEs, Grade ≥ 3 AEs, SAEs, and Cardiac AEs
ParticipantsAdjuvant Cross-Over Period: PH FDC SC in HospitalAdjuvant Cross-Over Period: PH FDC SC at Home
AEs9989
SAEs11
Cardiac AEs12
Grade ≥3 AEs63
SecondaryAdjuvant Cross-over Period: Number of Participants With Premature Withdrawal From PH FDC SC Due to AEs

An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study intervention. Participants who discontinued the study due to AEs are reported here.

Time frame:
Up to Cycle 6 (Cycle length = 21 days)
Reported as:
Count of participants · Participants
Adjuvant Cross-over Period: Number of Participants With Premature Withdrawal From PH FDC SC Due to AEs
ParticipantsAdjuvant Cross-Over Period: PH FDC SC in HospitalAdjuvant Cross-Over Period: PH FDC SC at Home
Adjuvant Cross-over Period: Number of Participants With Premature Withdrawal From PH FDC SC Due to AEs22
SecondaryTreatment Continuation Period and Trastuzumab Emtansine IV Period: Number of Participants With AEs, Grade ≥ 3 AEs, SAEs, and Cardiac AEs

AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with use of a study treatment, whether or not considered related to the study treatment. SAE=any untoward medical occurrence that, at any dose: Results in death; Is life threatening; Requires inpatient hospitalization/prolongation of existing hospitalization; Results in persistent disability/incapacity \&/or is a congenital anomaly/birth defect. Cardiac AEs=asymptomatic decline in LVEF of ≥10% from baseline to an LVEF \<50%; asymptomatic decline in LVEF requiring treatment/leading to discontinuation of study treatment; CHF. AEs ≥Grade 3=marked limitation of physical activity. Comfortable at rest, but any ordinary activity causes fatigue, palpitation/dyspnea; Inability to carry any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. Any physical activity leads to discomfort.

Time frame:
From initiation of study treatment until 28 days after the last treatment cycle (up to approximately 3.5 years)

Results for this outcome have not been posted.

SecondaryTreatment Continuation Period and Trastuzumab Emtansine IV Period: Number of Participants With Premature Withdrawal From PH FDC SC and Trastuzumab Emtansine IV Due to AEs

An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study intervention. Participants who discontinue study due to AEs will be reported.

Time frame:
From initiation of study treatment in the adjuvant phase until 28 days after the last treatment cycle (up to approximately 3.5 years)

Results for this outcome have not been posted.

Adverse events

Collected over From initiation of study treatment until 28 days after the last treatment cycle (Neoadjuvant phase: up to 7.4 months; Adjuvant phase: up to 12.3 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A, Neoadjuvant Phase: P+H IV0/115 (0%)19/115 (16.5%)113/115 (98.3%)
Arm B, Neoadjuvant Phase: PH FDC SC4/228 (1.8%)43/228 (18.9%)222/228 (97.4%)
Adjuvant Run-in Phase: PH FDC SC in Hospital0/194 (0%)3/194 (1.5%)84/194 (43.3%)
Adjuvant Cross-Over Phase: PH FDC SC in Hospital0/190 (0%)1/190 (0.5%)77/190 (40.5%)
Adjuvant Cross-Over Phase: PH FDC SC at Home0/191 (0%)1/191 (0.5%)64/191 (33.5%)
Adjuvant Continuation Phase: PH FDC SC in Hospital0/84 (0%)1/84 (1.2%)26/84 (31%)
Adjuvant Continuation Phase: PH FDC SC at Home0/114 (0%)0/114 (0%)31/114 (27.2%)
Arm E, Adjuvant Phase: Trastuzumab Emtansine IV1/117 (0.9%)9/117 (7.7%)107/117 (91.5%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SCAdjuvant Run-in Phase: PH FDC SC in HospitalAdjuvant Cross-Over Phase: PH FDC SC in HospitalAdjuvant Cross-Over Phase: PH FDC SC at HomeAdjuvant Continuation Phase: PH FDC SC in HospitalAdjuvant Continuation Phase: PH FDC SC at HomeArm E, Adjuvant Phase: Trastuzumab Emtansine IV
DiarrhoeaGastrointestinal disorders4/1157/2280/1940/1900/1910/840/1140/117
Febrile neutropeniaBlood and lymphatic system disorders0/1157/2280/1940/1900/1910/840/1141/117
AnaemiaBlood and lymphatic system disorders1/1154/2280/1940/1900/1910/840/1140/117
NeutropeniaBlood and lymphatic system disorders2/1154/2280/1940/1900/1910/840/1140/117
Postoperative wound infectionInfections and infestations2/1150/2281/1940/1900/1910/840/1140/117
Neutrophil count decreasedInvestigations2/1153/2280/1940/1900/1910/840/1140/117
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/1151/2280/1940/1900/1910/840/1140/117
ThrombocytopeniaBlood and lymphatic system disorders0/1153/2280/1940/1900/1910/840/1142/117
NauseaGastrointestinal disorders0/1153/2280/1940/1900/1910/840/1140/117
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1150/2280/1940/1900/1911/840/1140/117
Most frequent other events
Showing 10 of 62
Most frequent other events
EventArm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SCAdjuvant Run-in Phase: PH FDC SC in HospitalAdjuvant Cross-Over Phase: PH FDC SC in HospitalAdjuvant Cross-Over Phase: PH FDC SC at HomeAdjuvant Continuation Phase: PH FDC SC in HospitalAdjuvant Continuation Phase: PH FDC SC at HomeArm E, Adjuvant Phase: Trastuzumab Emtansine IV
DiarrhoeaGastrointestinal disorders72/115147/22812/1949/1907/1913/846/1147/117
NauseaGastrointestinal disorders64/115136/2285/1942/1902/1911/843/11418/117
AlopeciaSkin and subcutaneous tissue disorders57/115124/2283/1941/1900/1910/840/1143/117
AnaemiaBlood and lymphatic system disorders61/11596/2280/1945/1901/1911/842/11420/117
FatigueGeneral disorders41/11586/2289/1946/1902/1910/840/11417/117
ArthralgiaMusculoskeletal and connective tissue disorders13/11523/22811/1945/1908/1910/845/11431/117
NeutropeniaBlood and lymphatic system disorders22/11560/2282/1941/1904/1911/841/11422/117
VomitingGastrointestinal disorders25/11557/2281/1941/1901/1911/842/1146/117
Radiation skin injuryInjury, poisoning and procedural complications0/1153/22827/1945/1902/1910/840/11426/117
Aspartate aminotransferase increasedInvestigations11/11520/2281/1941/1901/1911/840/11426/117

Baseline characteristics

Neoadjuvant full analysis set (FASab) included all randomized participants, regardless of whether they received treatment. The HCPs were not enrolled in this study. Hence, no baseline data were planned to be collected for the HCPs responding to HCPQs.

Age, Continuous
Age, Continuous(years)Arm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SCTotal
Mean50.9 ± 11.052.9 ± 11.752.2 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Arm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SCTotal
Female116230346
Male011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SCTotal
Hispanic or Latino5293145
Not Hispanic or Latino54118172
Unknown or Not Reported102030
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A, Neoadjuvant Phase: P+H IVArm B, Neoadjuvant Phase: PH FDC SCTotal
American Indian or Alaska Native153550
Asian123244
Native Hawaiian or Other Pacific Islander011
Black or African American102333
White66123189
More than one race347
Unknown or Not Reported101323
08

Study locations

45 sites
  • Centro de Investigaciones Médicas y Desarrollo LC S.R.L
    Buenos Aires, Ciudad Autónoma de BuenosAires C1113AAE, Argentina
  • Centro Oncologico Korben
    Ciudad Autonoma Buenos Aires, C1426AGE, Argentina
  • University Clinical Center of the Republic of Srpska
    Banja Luka, 78000, Bosnia and Herzegovina
  • Cantonal Hospital Zenica
    Zenica, 72000, Bosnia and Herzegovina
  • Crio - Centro Regional Integrado de Oncologia
    Fortaleza, Ceará 60336-550, Brazil
  • Hospital Araujo Jorge
    Goiânia, Goiás 74605-070, Brazil
  • Hospital Nossa Senhora da Conceicao
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
    São Paulo, São Paulo 01317-001, Brazil
  • Multiprofile Hospital for Active Treatment Uni Hospital
    Panagyurishte, 4500, Bulgaria
  • Complex Oncology Center - Plovdiv First Internal Chemotherapy Department
    Plovdiv, 4004, Bulgaria
  • MHAT Nadezhda
    Sofia, 1330, Bulgaria
  • Royal Victoria Regional Health Centre
    Barrie, Ontario L4M 6M2, Canada
  • Lakeridge Health Oshawa
    Oshawa, Ontario L1G 2B9, Canada
  • North York General Hospital
    Toronto, Ontario M2K 1E1, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Hopital du Saint Sacrement
    Québec, Quebec G1S 4L8, Canada
  • Clinica Vespucio
    Santiago, 8241479, Chile
  • Centro de Estudios Clínicos SAGA
    Santiago, Chile
  • Clinica CIMCA
    San José, 10103, Costa Rica
  • ICIMED Instituto de Investigación en Ciencias Médicas
    San José, 10108, Costa Rica
  • Hospital Metropolitano (Sede Lindora-Santa Ana)
    San José, 10903, Costa Rica
  • Clinical Hospital Centre Zagreb
    Zagreb, 10000, Croatia
  • Saifee Hospital
    Mumbai, Maharashtra 400004, India
  • TATA Medical Centre
    Kolkata, West Bengal 700156, India
  • International Cancer Institute (ICI)
    Eldoret, 30100, Kenya
  • The Aga Khan University-Kenya.
    Nairobi, 00100, Kenya
  • Iem-Fucam
    D.F., Mexico City 04980, Mexico
  • Health Pharma Professional Research
    Mexico City, Mexico City 03100, Mexico
  • Oncologico Potosino
    San Luis Potosí City, San Luis Potosí 78209, Mexico
  • Instituto Regional de Enfermedades Neoplásicas del Sur
    Arequipa, 5154, Peru
  • Oncocenter Peru S.A.C.
    Lima, Lima 41, Peru
  • National Cancer Centre
    Singapore, 168583, Singapore
  • Tan Tock Seng Hospital
    Singapore, 308433, Singapore
  • Medical Oncology Centre of Rosebank
    Johannesburg, 2196, South Africa
  • Wilgers Oncology Centre
    Pretoria, 0001, South Africa
  • Korea University Anam Hospital
    Seoul, 02841, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico
    Jaén, 23007, Spain
  • Hospital Universitario Virgen de Arrixaca
    Murcia, 30120, Spain
  • Hospital Clinico Universitario de Salamanca
    Salamanca, 37007, Spain
  • Gulhane Training and Research Hospital
    Ankara, 06010, Turkey (Türkiye)
  • Ankara City Hospital
    Ankara, 06800, Turkey (Türkiye)
  • Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department
    Edirne, 22770, Turkey (Türkiye)
  • Ba?c?lar Medipol Mega Üniversite Hastanesi
    Istanbul, 34214, Turkey (Türkiye)
  • Hacettepe Uni Medical Faculty Hospital
    Sihhiye/Ankara, 06230, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Nov 2024, 28 months.

Results were first posted in Jan 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2022
First posted
Jun 13, 2022
StartActual
Jul 5, 2022
Primary completionActual
Nov 20, 2024
CompletionActual
Nov 7, 2025
Results first posted
Jan 12, 2026
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05415215
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 13, 2022
Start date
Jul 5, 2022
Primary completion
Nov 20, 2024
Completion
Nov 7, 2025
Results posted
Jan 12, 2026
Last update
Feb 10, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pertuzumab/Trastuzumab/Hyaluronidase-zzxf · Pertuzumab

Start the discussion